Systems, devices and methods for reducing glucose toxicity and restoring pancreatic beta cell function
The system adjusts insulin dosages in real-time based on frequent glucose measurements to achieve sustained glycemic balance and restore pancreatic beta cell function, addressing the limitations of existing diabetes management systems.
Patent Information
- Application Number
- CN202111131035.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2013-08-05
- Filing Date
- 2014-08-05
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing diabetes management systems fail to achieve sustained glycemic balance and restore pancreatic beta cell function in patients with advanced diabetes, due to infrequent medical professional interventions and the inability to predict dynamic insulin needs, leading to suboptimal glucose control and complications.
A system and method that adjusts insulin dosage regimens in real-time or near-real-time based on frequent blood glucose measurements, using a processor to determine and implement adjustments to maintain desired glycemic ranges, reducing glucose toxicity and restoring beta cell function.
Achieves sustained glycemic balance and reduces glucose toxicity by dynamically adjusting insulin dosages, potentially eliminating the need for frequent medical interventions and improving patient outcomes.
Smart Images

Figure CN113940627B_ABST
Abstract
Description
[0001] This application is a divisional application of a Chinese invention patent application filed on August 5, 2014, with application number 201480054905.5 and entitled “Systems, devices and methods for alleviating glucose toxicity and restoring pancreatic beta cell function in late-stage diabetes”.
[0002] Related Documents
[0003] This application is related to and claims the benefit of priority to U.S. Provisional Application Serial No. 61 / 862,327, filed on August 5, 2013. This application is also related to: U.S. Provisional Application Serial No. 61 / 042,487, filed on April 4, 2008; U.S. Provisional Application Serial No. 61 / 060,645, filed on June 11, 2008; U.S. Patent Application No. 12 / 417,955, filed on April 3, 2009, which was issued as U.S. Patent No. 8,600,682 on December 3, 2014 ... 960, which was issued as U.S. Patent No. 8,457,901 on June 4, 2013; U.S. Patent Application No. 13 / 168,659, filed on June 24, 2011; U.S. Patent Application No. 13 / 251,356, filed on October 3, 2011; U.S. Patent Application No. 13 / 868,612, filed on April 23, 2013; and U.S. Patent Application No. 14 / 067,479, filed on October 30, 2013. Each of these applications and patents is incorporated herein by reference in its entirety.
[0004] In addition, this application is related to PCT / US2009 / 039421, filed April 3, 2009; PCT / US2009 / 039418, filed April 3, 2009; U.S. Provisional Application Serial No. 61 / 113,252, filed November 11, 2008; U.S. Provisional Application Serial No. 61 / 257,866, filed November 4, 2009; PCT / US2009 / 063989, filed November 11, 2009; U.S. Provisional Application Serial No. 61 / 257,886, filed November 4, 2009; U.S. Patent Application Serial No. 12 / 926,234, filed November 3, 2010; and PCT / US2010 / 055246, filed November 3, 2010. Each of these applications and patents is incorporated herein by reference in its entirety. Finally, the reference to the work by Boyd and Vandenberghe, “Convex Optimization” (Cambridge University Press, 2004; ISBN-10:0521833787) is incorporated herein by reference in its entirety. Technical Field
[0005] The present application relates to systems, methods and / or devices for achieving glycemic balance in a diabetic patient, and more particularly to such systems, methods and / or devices, whereby a processor is programmed to determine, at least from data input corresponding to blood-glucose level measurements of the patient determined at multiple times, whether and to what extent to change at least one of one or more components of the patient's current insulin dosage regimen to achieve sustained glycemic balance, thereby reducing glucose toxicity and / or restoring pancreatic beta cell function. Background of the Invention
[0006] Diabetes mellitus ("DM" or "diabetes") is a chronic disease caused by a lack of insulin secretion by the beta cells of the endocrine pancreas. Approximately 7% of the general population in the Western Hemisphere suffers from diabetes. Roughly 90% of these people suffer from type 2 diabetes and approximately 10% suffer from type 1 diabetes. For type 1 diabetes, patients virtually abandon their endocrine pancreas due to an autoimmune disorder and thus gradually become dependent on daily insulin injections to control blood-glucose levels. On the other hand, for type 2 diabetes, the endocrine pancreas gradually fails to meet the increased insulin demand, requiring the patient to compensate with oral medications or insulin therapy regimens. In the case of either type 1 or type 2 diabetes, failure to properly control glucose levels in the patient's body may cause complications such as heart attack, stroke, blindness, renal failure, and even premature death.
[0007] Diabetes is a metabolic disorder in which an individual's ability to secrete insulin, and therefore regulate glucose levels, is impaired. For non-diabetic patients, normal glucose levels are typically about 85-110 mg / dl, and peak levels after meals typically reach about 140-200 mg / dl. Low glucose levels, or hypoglycemia, can drop below life-sustaining levels and lead to complications such as seizures, loss of consciousness, and even death. Prolonged high glucose levels, or hyperglycemia, have been associated with a much increased risk of complications such as heart disease, high blood pressure, kidney disease, and blindness, among others.
[0008] Insulin therapy is the mainstay of type 1 diabetes management and one of the most common treatments for type 2 diabetes, with approximately 27% of patients requiring insulin. The goal of insulin administration is to mimic physiological insulin secretion by introducing two types of insulin into the patient's body: long-acting insulin, which meets basal metabolic needs; and short-acting insulin (also known as rapid-acting insulin), which compensates for the acute rise in blood-glucose levels after a patient's meal. The elaboration of the process of administering these two types of insulin in any manner (e.g., separately or as premixed insulin) involves many considerations.
[0009] First, patients measure their blood-glucose levels (using some form of glucometer) about 3 to 4 times a day on average. The number of such measurements and the variations therebetween complicate the interpretation of these data, making it difficult to infer trends that can be used to better maintain the disease. Secondly, the complexity of human physiology constantly requires changes in the demand for insulin, to which frequent adjustments of insulin dosage regimens are necessary. At present, these considerations are handled by the patient's endocrinologist or other medical professionals during clinic appointments. Unfortunately, these visits are relatively infrequent - once every 3 to 6 months - and short in duration, so that doctors or other medical professionals are usually only able to review the latest patient medical data. As a result, it has been shown that more than 60% of patients control their diabetes at suboptimal levels, resulting in unwanted complications from the disease.
[0010] In fact, one of the major barriers to diabetes management is the lack of access to healthcare professionals and the relatively infrequent clinic appointments for patients. In fact, studies have determined that more frequent adjustments to insulin dosing regimens—such as every 1 to 2 weeks—improve diabetes control in most patients. However, as the number of patients with diabetes continues to expand, it is expected that the likelihood of more frequent adjustments to insulin dosing regimens through clinic visits will actually decrease. And, unfortunately, traditional diabetes treatment options do not address this barrier.
[0011] The most commonly used device in diabetes management is the glucose meter. The use of a glucose meter involves taking a blood sample from the patient and measuring its glucose content. Such devices come in various forms, although most are characterized by their ability to provide patients with nearly instantaneous readings of their blood-glucose levels. This additional information can be used to better identify dynamic trends in blood-glucose levels. However, conventional glucose meters are designed as diagnostic tools, not therapeutic tools. Therefore, even state-of-the-art glucose meters by themselves do not lead to improved glycemic control.
[0012] A conventional solution for treating diabetes is the insulin pump. An insulin pump is a device that continuously injects short-acting insulin into a patient at a predetermined rate to meet basic needs and meals. The use of an insulin pump involves inserting a catheter into the patient's body through which insulin is infused. In the case of manual insulin administration therapy, a medical professional sets up the pump for the patient's insulin dosage regimen during a clinic visit. In addition to the considerable daily cost of insulin pumps, which hinders their widespread use by patients with type 2 diabetes, they also require frequent adjustments by a physician or other medical professional to compensate for the needs of individual patients based on frequent blood-glucose-level measurements.
[0013] An even more recent solution to diabetes treatment attempts to combine an insulin pump with near-continuous blood glucose monitoring to, in effect, attempt to create an artificial pancreas that regulates the patient's blood-glucose-levels through the infusion of short-acting insulin. According to this solution, real-time patient information is used to match insulin dosage to the patient's dynamic insulin needs, regardless of any underlying physician-prescribed treatment regimen. Although such systems address current dosage requirements, they are fully responsive rather than immediately effective. Due to these deficiencies, such combined systems are not always able to effectively control blood glucose levels. For example, such combined devices cannot predict unplanned activities, such as exercise, that may excessively reduce the patient's blood glucose level. And when a hypoglycemic situation is detected, the delay in insulin effectiveness caused by not only the properties of conventional synthetic insulin, but also by the subcutaneous delivery of the insulin by conventional pumps leads to inefficient correction of hypoglycemic events.
[0014] The most common biomarker for achieving glycemic control is hemoglobin A1C (A1C for brevity). The relationship between average glucose levels and A1C has been studied. For healthy individuals, A1C is between 4.6% and 5.8%, and for diabetic patients, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommend maintaining A1C <7%, which is associated with an average glucose level below 150 mg / dl.
[0015] Studies have demonstrated the relationship between A1C and complications. The ADA and EASD have set a goal of keeping A1C below 7%. This was chosen as a compromise between reducing the risk of complications and the risk of severe (and potentially fatal) hypoglycemia. As a result, diabetes management has evolved with the primary goal of getting A1C down, as reflected in several consensus statements issued by the various agencies.
[0016] While the aforementioned solutions are beneficial, or at least hold promise, in managing and treating diabetes in some patients, existing models have not been able to achieve the reduction of glucose toxicity and restoration of beta cell function in patients with advanced diabetes. Thus, there continues to be a need for systems, devices, and / or methods that can achieve blood glucose homeostasis, reduce glucose toxicity, and / or restore beta cell function in patients with long-term illness. SUMMARY OF THE INVENTION
[0017] Certain embodiments relate to systems, devices and / or methods for treating diabetes in a patient by providing treatment guidance. For example, a method for treating diabetes by reducing glucose toxicity and / or restoring pancreatic beta cell function in a patient, the method comprising: storing one or more components of the patient's insulin dosage regimen; drawing blood samples from the patient at multiple times; determining blood glucose-level measurements of the patient in the blood samples; marking each of the blood glucose-level measurements with an identifier reflecting when the measurement was obtained; establishing the patient's current glycemic state relative to a desired glycemic range; determining whether and to what extent to adjust at least one of the one or more components of the patient's current insulin dosage regimen based on the patient's blood glucose-level measurements to remain within the desired glycemic range and administer a minimum insulin dose; adjusting the at least one component based on the determination; and performing the steps of the method until the insulin dosage regimen required to remain within the desired glycemic range is reduced to a predetermined level.
[0018] In certain embodiments, adjustments to the patient's insulin dosage regimen can be made in substantially real time.
[0019] In certain embodiments, the initial insulin dosage regimen may be provided by a physician or other medical professional.
[0020] In certain embodiments, the method can be performed without any intervention by a physician or other medical professional.
[0021] In certain embodiments, the desired blood glucose range may change over time and adjustments to the patient's insulin dosage regimen may be made to be within the most recent desired blood glucose range.
[0022] In certain embodiments, the identifier reflecting when the reading was obtained can be selected from breakfast, lunch, dinner, bedtime, nighttime, and others.
[0023] In certain embodiments, measurements labeled "Other" may be categorized based on the categorization of a previous measurement and the time that has passed since the previous measurement.
[0024] In certain embodiments, the desired blood glucose range can be defined as blood glucose-level measurements between 85 mg / dL and 200 mg / dL.
[0025] In certain embodiments, the steps of the method may be repeated for a sufficient time to achieve sustained glycemic balance.
[0026] In certain embodiments, the patient's insulin dosage regimen may be adjusted to include at least one high insulin dose.
[0027] In certain embodiments, the patient's insulin dosage regimen may be adjusted so that no insulin is no longer administered.
[0028] Certain embodiments relate to systems, devices and / or methods for treating diabetes in a patient by providing treatment guidance. For example, a method for treating diabetes by reducing glucose toxicity and / or restoring pancreatic beta cell function in a patient, the method comprising: storing one or more components of the patient's insulin dosage regimen; drawing blood samples from the patient at multiple times; determining blood glucose-level measurements of the patient in the blood samples; marking each of the blood glucose-level measurements with an identifier reflecting when the measurement was obtained; establishing the patient's current glycemic state relative to a desired glycemic range; determining whether and to what extent to adjust at least one of the one or more components of the patient's current insulin dosage regimen based on the patient's blood glucose-level measurements to remain within the desired glycemic range and administer a minimum insulin dose; adjusting the at least one component based on the determination in a manner that suppresses or prevents unstable oscillations; and performing the steps of the method until the insulin dosage regimen required to remain within the desired glycemic range is reduced to a predetermined level.
[0029] In certain embodiments, such unstable oscillations may be suppressed or prevented by ensuring that the adjustments are limited to intermittent values.
[0030] In certain embodiments, the unstable oscillations can be suppressed or prevented by ensuring that the current increase in the patient's insulin dosage regimen is less than the previous decrease in the patient's insulin dosage regimen.
[0031] In certain embodiments, the unstable oscillations can be suppressed or prevented by ensuring that the current decrease in the patient's insulin dosage regimen is less than the previous increase in the patient's insulin dosage regimen.
[0032] In certain embodiments, such unstable oscillations may be suppressed or prevented by inserting 'off intervals' between dose adjustments in different directions.
[0033] In certain embodiments, a determination of whether and by how much to adjust at least one component of the patient's current insulin dosage regimen can be made by calculating the total daily amount of insulin.
[0034] In certain embodiments, a determination of whether and by how much to adjust at least one component of the patient's current insulin dosage regimen can be made by calculating the amount by which any component of the dosage is greater than the same component of a previous dosage.
[0035] In certain embodiments, the determination of whether and by how much to adjust at least one component of the patient's current insulin dosage regimen may be made by majority voting rule.
[0036] In certain embodiments, the determination of whether and by how much to adjust at least one component of the patient's current insulin dosage regimen may be subject to a continuous dosage increment rule such that an off period is established if more than a desired number of increments have occurred.
[0037] In certain embodiments, the sequential dose increment rule can prevent two consecutive increments from occurring and establish a rest period after each dose increment.
[0038] In certain embodiments, the sequential dose increment rule may allow for more than two sequential increments, but no more than eight sequential increments.
[0039] Certain embodiments relate to systems, devices and / or methods for treating diabetes in a patient by providing treatment guidance. For example, a method for updating a patient's insulin dosage regimen to reduce glucose toxicity and / or restore pancreatic beta cell function, the method comprising: storing one or more components of the patient's insulin dosage regimen; drawing blood samples from the patient at multiple times; determining blood glucose-level measurements of the patient in the blood samples; incrementing a timer based on at least one of the passage of a predetermined amount of time and the receipt of each blood glucose-level measurement; marking each of the blood glucose-level measurements with an identifier reflecting when the measurement was obtained; establishing the patient's current glycemic state relative to a desired glycemic range; determining whether and to what extent at least one of the one or more components of the patient's current insulin dosage regimen should be adjusted based on the patient's blood glucose-level measurement to remain within the desired glycemic range with the lowest insulin dose; updating the at least one component in the patient's insulin dosage regimen in response to the determination; and performing the above steps of the method until the insulin dosage regimen required to remain within the desired glycemic range is reduced to a predetermined level.
[0040] In certain embodiments, a determination is made that there have been an excessive number of blood-glucose measurements that are not within the desired glycemic range with the lowest insulin dose within a predetermined time period, and in response to the determination, an update of at least one of the one or more components of the patient's insulin dosage regimen may be completed; and the timer may be reset.
[0041] In certain embodiments, the timer can be configured to indicate that the step of determining whether and to what extent at least one of the one or more components of the patient's current insulin dosage regimen should be adjusted based on the patient's blood glucose-level measurement should be performed after 7 days.
[0042] In certain embodiments, the timer can indicate when to perform the step of determining whether and to what extent at least one of the one or more components of the patient's current insulin dosage regimen should be adjusted based on the patient's blood glucose-level measurement, and the timer can be reset.
[0043] In certain embodiments, the desired blood glucose range may change over time and updates to the patient's insulin dosage regimen may be made to the most recent desired blood glucose range.
[0044] In certain embodiments, the patient's insulin dosage regimen can be updated in a manner that dampens or prevents unstable oscillations.
[0045] In certain embodiments, the extent of the oscillation can be reduced by ensuring that the current increase in the patient's insulin dosage regimen is less than the previous decrease in the patient's insulin dosage regimen.
[0046] In certain embodiments, the identifier reflecting when the reading was obtained can be selected from breakfast, lunch, dinner, bedtime, nighttime, and others.
[0047] In certain embodiments, measurements labeled "Other" may be categorized based on the categorization of a previous measurement and the time that has passed since the previous measurement.
[0048] In certain embodiments, the desired blood glucose range can be defined as blood glucose-level measurements between 85 mg / dL and 200 mg / dL.
[0049] In certain embodiments, the steps of the method may be repeated for a sufficient time to achieve sustained glycemic balance.
[0050] In certain embodiments, the patient's insulin dosage regimen may be updated to include at least one high insulin dose.
[0051] In certain embodiments, the patient's insulin dosage regimen may be updated so that no insulin is no longer administered.
[0052] Certain embodiments relate to systems, devices, and / or methods for treating diabetes in a patient by providing treatment guidance. For example, a device for alleviating glucose toxicity and / or restoring pancreatic beta cell function in a patient over time comprises: at least a first computer-readable memory for storing one or more components of a patient's current insulin dosage regimen and blood-glucose-level measurements of the patient measured at multiple times over a predetermined time period; at least one data input for obtaining data corresponding to the patient's blood glucose-level measurements measured at the multiple times; a timer for monitoring the predetermined time period, the timer being incremented based on at least one of the passage of a predetermined time increment and the receipt of at least one of a plurality of blood glucose-level measurements; at least one processor operably connected to the at least first computer-readable memory, the processor being programmed to at least: mark the plurality of blood glucose-level measurements with an identifier reflecting when the measurement was obtained; after obtaining one of the plurality of blood glucose-level measurements, but before obtaining a subsequent blood glucose-level measurement, calculate the obtained blood glucose-level measurement; any deviation of the blood glucose-level measurement from the expected glycemic range; adjusting at least one of the one or more components of the patient's insulin dosage regimen in response to a determination that the most recently obtained blood glucose-level measurement is not within the expected glycemic range; wherein the timer is reinitialized after a determination that the most recently obtained blood glucose-level measurement is not within the expected glycemic range within the predetermined time period; at the end of the predetermined time period, determining, based on a plurality of data corresponding to the patient's blood glucose-level measurement, a change in at least one of the one or more components of the patient's insulin dosage regimen that is necessary to maintain the patient's blood glucose-level measurement within the predetermined range; reinitializing the timer after said adjustment and said determination; and repeatedly marking said measurement, calculating said deviation, adjusting said at least one component, and determining said change until the insulin dosage regimen required to remain within the expected glycemic range is reduced to a predetermined level.
[0053] In certain embodiments, the data input device may enable a user to modify the identifier associated with each blood-glucose-level measurement data-input.
[0054] In certain embodiments, the at least one processor may further determine on a predetermined schedule whether and to what extent to change at least one of the one or more components of the patient's current insulin dosage regimen.
[0055] In certain embodiments, the at least one processor may further determine, at the end of the predetermined time period, whether the patient's blood-glucose level measurement value falls within or outside the predetermined range based on the multiple data corresponding to the patient's blood-glucose level measurement value, and change at least one of the one or more components in the patient's current insulin dosage regimen only when the patient's blood-glucose level measurement value falls outside the predetermined range.
[0056] In certain embodiments, the at least one processor may further determine based on the patient's blood-glucose-level measurements whether the patient's blood-glucose-level measurements represent a normal distribution.
[0057] In certain embodiments, determining whether the patient's blood-glucose-level measurements represent a normal distribution may include determining whether a third moment of the distribution of the patient's blood-glucose-level measurements falls within the predetermined range.
[0058] In certain embodiments, the one or more components of the patient's current insulin dosage regimen may include a long-acting insulin dosage component.
[0059] In certain embodiments, the one or more components of the patient's current insulin dosage regimen may include a short-acting insulin dosage component defined by a carbohydrate ratio or fixed meal dose, and a plasma glucose correction factor.
[0060] Certain embodiments relate to systems, devices, and / or methods for treating diabetes in a patient by providing treatment guidance. For example, a system for alleviating glucose toxicity and / or restoring pancreatic beta cell function in a patient, the system comprising: at least one memory for storing data corresponding to at least one or more components of the patient's current insulin dosage regimen, and at least data corresponding to blood-glucose-level measurements of the patient measured at multiple times during a predetermined time period; and at least one processor operably connected to the at least one memory, the at least one processor being configured to: initialize a timer to monitor the predetermined time period; increment the timer based on at least one of the passage of a predetermined time increment and the receipt of at least one of a plurality of blood glucose-level measurements; tag the plurality of blood glucose-level measurements with an identifier reflecting when the measurement was obtained; after obtaining one of the plurality of blood glucose-level measurements, but before obtaining a subsequent blood glucose-level measurement, calculate any deviation of the obtained blood glucose-level measurement from an expected glycemic range; in response to a predetermined time increment, calculate a predetermined time increment based on the passage of a predetermined time increment and the receipt of at least one of a plurality of blood glucose-level measurements; ... adjusting at least one of the one or more components of the patient's insulin dosage regimen in response to a determination that a most recently obtained blood glucose-level measurement is not within an expected glycemic range; wherein the timer is reinitialized after the determination that it is not within the expected glycemic range; and at the end of the predetermined time period, determining whether and to what extent to change at least one of the one or more components of the patient's current insulin dosage regimen in order to maintain the patient's blood glucose-level measurement within a predetermined range based on a plurality of data corresponding to the patient's blood glucose-level measurement; wherein the timer is reinitialized after the determination whether and to what extent to change at least one of the one or more components of the patient's current insulin dosage regimen; and repeatedly incrementing the timer, marking the measurement, calculating the deviation, adjusting the at least one component, and determining the change until the insulin dosage regimen required to remain within the expected glycemic range is reduced to a predetermined level.
[0061] In some implementations, the at least one memory and the at least one processor may be located in a single device.
[0062] In certain embodiments, the single device may further include a blood glucose meter.
[0063] In certain embodiments, the system may further include a blood glucose meter separate from the single device, which may be adapted to transmit to the at least one memory of the single device data corresponding at least to blood-glucose-level measurements of the patient determined at multiple times.
[0064] In certain embodiments, the single device may further comprise data input means for inputting data corresponding at least to blood-glucose-level measurements of the patient determined at a plurality of times directly into the at least one memory.
[0065] In certain embodiments, the system may further include a data input device, which is disposed at a remote location of the single device, for remotely inputting data corresponding to at least the one or more components of the patient's current insulin dosage regimen into the at least one memory.
[0066] In certain embodiments, the system may further include at least a first data input device, which is disposed at a remote location from the at least one memory and the at least one processor, for remotely inputting data corresponding to at least one or more components in the patient's current insulin dosage regimen into the at least one memory; and at least a second data input device, which is disposed at a remote location from the at least one memory, the at least one processor, and the at least first data input device, for remotely inputting data corresponding to at least blood-glucose level measurements of the patient measured at multiple times into the at least one memory.
[0067] In certain embodiments, the data corresponding at least to blood-glucose-level measurements of the patient determined at a plurality of times may be associated with an identifier indicating when the measurements were entered into the memory.
[0068] In certain embodiments, the system may further comprise a data input device enabling a user to define the identifier associated with the blood-glucose-level measurement data.
[0069] In certain embodiments, the system may further comprise a data input device enabling a user to confirm the correctness of the identifier associated with the blood-glucose-level measurement data.
[0070] In certain embodiments, the system may further comprise a data input device enabling a user to modify the identifier associated with each blood-glucose-level measurement data.
[0071] In certain embodiments, the processor can be programmed to determine on a predetermined schedule whether and by what extent to change at least one of the one or more components of the patient's current insulin dosage regimen.
[0072] In certain embodiments, the processor can be programmed to determine whether the patient's blood-glucose level measurements fall within or outside of the expected glycemic range based on data input corresponding at least to blood-glucose level measurements of the patient measured at multiple times, and to change at least one of the one or more components of the patient's current insulin dosage regimen only when the patient's blood-glucose level measurements fall outside of the expected glycemic range.
[0073] In certain embodiments, the processor can be further programmed to determine whether the patient's blood-glucose level measurements measured at multiple times represent a normal or non-normal distribution based on at least the data input corresponding to the patient's blood-glucose level measurements measured at multiple times.
[0074] In certain embodiments, determining whether the patient's blood-glucose level measurements measured at multiple times represent a normal or non-normal distribution can include determining whether the third moment of the distribution of the patient's blood-glucose level measurements measured at multiple times falls within the expected glycemic range.
[0075] In certain embodiments, the one or more components in the patient's current insulin dosage regimen may include a long-acting insulin dosage component, and the processor may be programmed to determine whether the measurement is a morning or a bedtime blood-glucose level measurement based at least on the identifier indicating when the measurement was entered into the memory, to determine whether the patient's morning and bedtime blood-glucose level measurements fall within a predetermined range, and to determine to what extent to change the patient's long-acting insulin dosage component only if it is determined that the patient's morning and bedtime blood-glucose level measurements fall outside of the expected glycemic range.
[0076] In certain embodiments, in connection with determining by what degree to change at least one of the one or more components of the patient's current insulin dosage regimen, the at least one processor can be programmed to factor in an insulin sensitivity correction factor that defines the percentage by which any of the one or more components of the insulin dosage regimen can be changed and the direction by which any fractional changes in any of the one or more components are rounded to the nearest integer.
[0077] In certain embodiments, the at least one memory may further store data corresponding to the patient's current weight, and the insulin sensitivity correction factor may be determined based in part on the patient's current weight.
[0078] In certain embodiments, the determination of how much to alter the long-acting insulin dosage component of the patient's current insulin dosage regimen can be a function of the current long-acting insulin dosage, the insulin sensitivity correction factor, and the patient's blood-glucose-level measurements.
[0079] In certain embodiments, the one or more components of the patient's current insulin dosage regimen may include a short-acting insulin dosage component defined by a carbohydrate ratio and a plasma glucose correction factor, and the processor may be programmed to determine whether and to what extent to change the patient's carbohydrate ratio and plasma glucose correction factor.
[0080] In certain embodiments, in connection with determining the extent to which to change at least one of the one or more components of the patient's current insulin dosage regimen, the at least one processor can be programmed to take into account an insulin sensitivity correction factor that defines the percentage by which any one or more components of the insulin dosage regimen can be changed and the direction in which any fractional changes in the one or more components are rounded to the nearest integer.
[0081] In certain embodiments, the determination of the current plasma glucose correction factor as to how much to change the patient's insulin dosage regimen can be a function of a predetermined value divided by the total daily dose of insulin administered to the patient, the patient's current plasma glucose correction factor, and the average of the insulin sensitivity correction factor.
[0082] In certain embodiments, a value representing twice the patient's daily dose of long-acting insulin in the current insulin dosage regimen is substituted as an approximation of the average total daily dose of insulin administered to the patient.
[0083] In certain embodiments, the plasma glucose correction factor component of the patient's insulin dosage regimen can be quantified into predetermined steps of mg / dL.
[0084] In certain embodiments, the determination of how much to change the current carbohydrate ratio component of a patient's insulin dosage regimen can be a function of a predetermined value divided by the average of the total daily dose of insulin administered to the patient, the patient's current carbohydrate ratio, and the insulin sensitivity correction factor.
[0085] In certain embodiments, a value representing twice the patient's daily dose of long-acting insulin in the current insulin dosage regimen is substituted as an approximation of the average total daily dose of insulin administered to the patient.
[0086] In certain embodiments, the at least one processor can be programmed to determine a correction factor that allows for variations in changes to the carbohydrate ratio component of a patient's insulin dosage regimen to compensate for the patient's individual response to insulin at different times of the day.
[0087] In certain embodiments, the one or more components of the patient's current insulin dosage regimen may include a long-acting insulin dosage component, and the determination of the extent to which to change the long-acting insulin dosage component may be limited to a change amount within a predetermined range.
[0088] In certain embodiments, the one or more components in the patient's current insulin dosage regimen may include a short-acting insulin dosage component defined by a carbohydrate ratio and a plasma glucose correction factor, and the determination of the extent to which any one or more of the components in the short-acting insulin dosage component are changed may be limited to a change within a predetermined range.
[0089] In certain embodiments, the one or more components of the patient's current insulin dosage regimen may include a short-acting insulin dosage component taken according to a sliding scale, and the processor may be programmed to determine whether and to what extent to change at least the sliding scale in order to keep future blood-glucose level measurements of the patient within a predetermined range.
[0090] In some embodiments, the determination of how much to change the scaling can be limited to a change within a predetermined range. BRIEF DESCRIPTION OF THE DRAWINGS
[0091] The accompanying drawings facilitate understanding of various embodiments of the present technology.
[0092] Figure 1 is a simplified schematic diagram of an apparatus according to certain exemplary embodiments.
[0093] Figure 2 is a diagram of a representative display used to provide information to a patient.
[0094] Figure 3 is a diagram of another representative display for providing information to a patient.
[0095] Figure 4 is a diagram of yet another representative display for providing information to a patient.
[0096] Figure 5 is a diagram of yet another representative display for providing information to a patient.
[0097] Figure 6is a simplified diagram of an apparatus for employing the disclosed system, according to certain embodiments thereof.
[0098] Figure 7 is a simplified diagram of an apparatus for employing the disclosed system, according to certain embodiments.
[0099] Figure 8 is a simplified diagram of an apparatus for employing the disclosed system, according to certain embodiments thereof.
[0100] Fig. 9 is a schematic representation of an exemplary apparatus according to certain embodiments.
[0101] Fig.10 is a schematic diagram of an exemplary apparatus for use according to certain embodiments.
[0102] Fig.11 is a generalized block diagram of steps taken in updating a patient's insulin dosage regimen, according to certain exemplary embodiments.
[0103] Fig.12 is a flow chart of an exemplary algorithm employed in updating a patient's insulin dosage regimen, according to certain exemplary embodiments.
[0104] Fig.13 A subject with low variability in glucose levels is shown.
[0105] Fig.14 A subject with high variability in glucose levels is shown.
[0106] Fig.15 Patients with varying levels of glycemic variability are shown.
[0107] Fig.16 A subject with high glucose levels and low variability is shown.
[0108] Fig.17 Insulin dosing for a subject with high glucose levels and low variability is shown.
[0109] Fig.18 A subject with high variability and low glucose is shown.
[0110] Fig.19 Insulin doses for subjects with high variability and low glucose are shown.
[0111] Fig. 20 Subjects with low variability and low glucose are shown.
[0112] Fig.21 Insulin doses for subjects with low variability and low glucose are shown.
[0113] Fig. 22 A subject with high variability and high glucose is shown.
[0114] Fig.23 Insulin doses are shown for a subject with high variability and high glucose.
[0115] Fig.24 Blood glucose levels of subjects on premix insulin therapy are shown.
[0116] Fig.25 Insulin doses for subjects on premix insulin therapy are shown.
[0117] Fig.26 Blood glucose levels of subjects on premix insulin therapy are shown.
[0118] Fig. 27 Insulin doses for subjects on premix insulin therapy are shown.
[0119] Fig.28 Blood glucose levels are shown for a subject taking a relatively small daily total of -45 units / day divided almost evenly between basal and bolus.
[0120] Fig.29 Insulin doses are shown for a subject taking a relatively small daily total of -45 units / day that was split almost evenly between basal and bolus.
[0121] Fig.30 Shown is the weekly average glucose (and regression line) cumulatively for all patients in this example, according to certain embodiments.
[0122] Fig.31 Shown are the weekly average glucose (and regression line) for Groups I and II in this example, cumulatively, according to certain embodiments.
[0123] Fig.32 Shown are weekly average glucose in Group III in this example (no regression line is drawn due to the small number of data points), according to certain embodiments.
[0124] Fig.33 Weekly average glucose (and regression line) for patients with and without frequent hypoglycemia are shown. According to certain embodiments, weekly average glucose was increased during the active 12-week period when possible in this example.
[0125] Fig.34 Shown is the distribution of hypoglycemic glucose readings during the 12-week active phase and the 4-week run-in phase in this example, according to certain embodiments.
[0126] Fig.35The frequency of mild hypoglycemia (glucose <65 mg / dl) during each quartile for patients with and without frequent hypoglycemia (>85 events per patient per year) in this example is shown, according to certain embodiments.
[0127] Fig.36 Total daily insulin in patients with varying frequencies of mild hypoglycemia is shown. According to certain embodiments, during the active 12 cycles, the frequency and severity of hypoglycemia decreases.
[0128] Fig.37 Shown are insulin doses and mean blood glucose levels for subjects on insulin therapy over a 9 month period.
[0129] Fig.38 Shown are insulin doses and mean blood glucose levels for subjects on insulin therapy over a period of 15 months.
[0130] Fig.39 Shown are insulin doses and mean blood glucose levels for subjects on insulin therapy over a 10 month period. DETAILED DESCRIPTION OF THE INVENTION
[0132] The following description is provided with respect to several embodiments that can share common characteristics and features. It should be understood that one or more features of any one embodiment can be combined with one or more features of other embodiments. In addition, any single feature or combination of features in any embodiment can constitute additional embodiments.
[0133] In this specification, the word "comprising" is to be understood in its "open" sense, i.e. in the sense of "including", and is therefore not limited to its "closed" sense, i.e. in the sense of "consisting only of". When it appears, the corresponding meaning is attributed to the respective words "including" and "comprising".
[0134] The subject headings used in the Detailed Description of the Invention are included only for the convenience of the reader's reference and should not be used to limit the subject matter found in the entire disclosure or claims. The subject headings should not be used to interpret the scope of the claims or the limitations of the claims.
[0135] As herein used term " insulin dosage function " or " IDF " about some embodiment, refer to the checklist of insulin regimen, agreement or its combination that the user is instructed to follow.For example, for the patient who follows the premixed insulin regimen, this insulin dosage function can comprise two digits that reflect two insulin injections per day (for example X insulin unit after breakfast and Y insulin unit after dinner) that are associated with two events.As herein used term IDF history about some embodiment, refer to the chronology of insulin dosage function and external insulin dosage function that are regarded as a data group.First IDF in the IDF history is active insulin dosage function or the checklist that is used to recommend the suitable insulin dosage of each particular event and event-related information to the user at present.The following record is the second IDF in the IDF history, and the following is the 3rd IDF in the IDF history, and the existing record that runs through the IDF history like this.
[0136] As used herein with respect to certain embodiments, the term "partial update" refers to the operation of updating a single dosage component in an insulin dosage function. In certain embodiments, a partial update may change more than one dosage component. In certain embodiments, a partial update may not interfere with the synchronous dosage adjustment frequency. In certain embodiments, when the time for performing synchronous adjustment expires, the event causing the partial update may be excluded.
[0137] As used herein about some embodiment, term " updating completely " refers to assessment insulin dosage component, to determine whether and to what degree change one or more operations of dosage component.In some embodiments, the operation of updating completely causes the resetting of synchronous clock.In some embodiments, the operation of updating completely may cause data from the assessment period to expire.For example, some embodiments can adopt counter to determine the quantity of hypoglycemic events that occur in given time interval, and the process of updating completely may cause the resetting of described counter.
[0138] As used herein with respect to certain embodiments, the term "severe hypoglycemic event" or "SHE" refers to a blood glucose value below a certain threshold. In certain embodiments, a severe hypoglycemic event is a patient history event with glucose data less than 55 mg / dl. In certain embodiments, a severe hypoglycemic event is a patient history event with glucose data less than 40, 45, 50, 55, 60, 65, 70 mg / dl, or a combination thereof.
[0139] Certain embodiments relate to a therapeutic device, which is a blood glucose meter equipped with artificial intelligence (AI) and can optimize the drug dosage of patients treated with various types of insulin, including optimizing the combination of insulin types (i.e., short-acting and long-acting insulin). Certain embodiments monitor patient glucose readings and other parameters and modify insulin dosage as needed in a manner similar to that which an endocrinologist or other qualified health care provider would take when the person continuously obtains the patient's data. Optimal dosage levels are achieved by dynamically modifying drug dosage based on personal lifestyle and changing needs. In turn, this also leads to excellent glycemic control and better patient prognosis.
[0140] Blood sugar balance
[0141] The goal of diabetes management can be to achieve glycemic balance and / or an improved glycemic composite index (GCI) weighted for both A1C and hypoglycemia. Another goal of diabetes management can bring patients close to glycemic balance and / or at least an improved GCI weighted for A1C and hypoglycemia. Another goal of diabetes management can be to alleviate glucose toxicity and / or restore pancreatic beta cell function by achieving glycemic balance and / or improved GCI. There are several possible methods for minimizing a combination of two parameters (sometimes referred to as minimizing the cost function of two independent variables (arguments)). The definition of the cost function itself is important because its form can determine what type of solution to the minimization problem exists. Convex cost functions can be minimized by several methods and the smallest solution is unique. The optimization of convex functions has been well studied and books such as "Convex Optimization" by Boyd and Vandenberghe (Cambridge University Press, 2004; ISBN-10:0521833787) describe several known methods for performing such optimization. Unfortunately, there is no widely accepted definition of what is an "acceptable low blood sugar level". However, the purpose of some aspects of the present disclosure is to set a goal of achieving better glycemic balance or improved GCI by minimizing one independent variable while making an effort to keep another independent variable under a certain threshold. The purpose of some aspects of the present disclosure is to set a goal of guiding the subject to glycemic balance or improved GCI by minimizing one independent variable while making an effort to keep another independent variable under a certain threshold. For example, a possible method is to minimize the glycemic index (GI) as long as it is above a certain threshold while keeping the frequency of hypoglycemia below another threshold; wherein GI is a set of measures that reduce multiple historical blood glucose levels to a single variable. For example, GI can be the average or median of a given set of glucose values. Other metrics can also be combined, such as minimum, maximum, minimum of average or median, and other combinations, like pattern recognition that can reduce multidimensional data sets to a single value. In certain embodiments, assuming that the glycemic index is above 120 mg / dl and as long as there are no more than 3 low blood glucose values during the observation period, it may be desirable to increase one or more of the insulin dosage components to reduce the glycemic index. If the glycemic index is above 150, 140, 130, 110, 100, 90 or 80 mg / dl and as long as there are no more than 1, 2, 4, 5, 6, 7, 8, 9 or 10 low blood glucose values during the observation period, other quantities may also be considered, such as increasing one or more of the insulin dosage components. In certain embodiments, low blood glucose values may be limited to glucose levels below 80, 75, 70, 65, 60, 55, 50 or 45 mg / dl. Other methods as disclosed herein may also be selected.
[0142] In some embodiments, as usually done in constrained optimization, a dual approach is to reduce the frequency of hypoglycemia, as long as GI is below a certain threshold. For example, in some embodiments, if the frequency of hypoglycemia exceeds 3 times during the observed interval, and as long as GI is lower than 200 mg / dl, it may be desirable to reduce one or more of the insulin dosage components. Other values, like 1,2,4,5,6,7 or 8 hypoglycemic episodes can be combined with blood glucose, and indices lower than 250,240,230,220,210,190,180,170,160,150,140,130,120 also can be used.
[0143] For example, to improve GCI, some embodiments may choose to reduce average glucose as long as the hypoglycemia rate does not exceed a certain threshold. An exemplary algorithm to achieve this may be described as follows:
[0144] Count the number of hypoglycemic episodes in a given period of time to determine the hypoglycemia rate (HR)
[0145] If HR>N
[0146] Lower insulin levels
[0147] otherwise
[0148] Calculating the Glycemic Index (GI)
[0149] If GI <A1
[0150] Reduce insulin dose
[0151] If GI>A2
[0152] Increase insulin dose.
[0153] The unacceptable hypoglycemia rate threshold (N) can be set to 80 events / year, although other numbers, such as 50, 60, 70, 75, 85, 90, 100, 110 or 120 events / year can also be used. The other two thresholds A1 and A2 can be selected to drive the GI to the desired target. For example, a lower level of 80 mg / dl and a higher level of 130 mg / dl can be set, although other digital combinations can also be used. For example, a glucose value of 60, 65, 70, 75, 85, 90, 95, 100, 105 or 110 mg / dl can be used as the lower threshold A1, and a glucose value of 110, 115, 120, 125, 135, 140, 145, 150, 155 or 160 mg / dl can be used as the upper threshold A2.
[0154] The GI is based on various statistics that can be derived from the available glucose data. For example, the statistics that can be used are mean, median, minimum, maximum, other mathematical operators that can be extracted from a specific set of glucose data (e.g., pattern detection), or a combination thereof.
[0155] Alleviate glucose toxicity and restore β-cell function
[0156] Type 2 diabetes is increasing worldwide with the age of onset decreasing. It is characterized by insulin resistance, a physiological condition in which insulin-sensitive tissues within the body (i.e., muscle, fat, and liver) fail to respond to the normal actions of the hormone insulin or have at least reduced responsiveness to the normal actions of insulin. Insulin resistance in muscle and fat cells may reduce glucose uptake, while insulin resistance in liver cells may reduce inhibition of glucose production and / or release, leading to increased insulin and glucose levels in the blood. If insulin resistance is present, more insulin may need to be secreted by the pancreas.
[0157] The ability to secrete sufficient amounts of insulin can be determined by the functional integrity of the β cells and their overall quality. Although insulin resistance and mild elevations in ambient glucose (i.e., impaired fasting glucose and impaired glucose tolerance) can persist for decades, excessive hyperglycemia usually progresses over a period of several years. Hyperglycemia can be toxic to a variety of tissues, including pancreatic β cells. Injured β cells can secrete less insulin, which can cause more severe hyperglycemia. Once full-blown hyperglycemia has progressed, it may impose further metabolic damage to pancreatic β cells, which may lead to further insulin deficiency and / or additional hyperglycemia, and may ultimately lead to β cell death. The adverse effects of excessive glucose concentrations can be referred to as "glucose toxicity." This pathophysiological vicious cycle may be one of the main reasons for the progressiveness of diabetes.
[0158] Long-term maintenance of β-cell function can improve long-term glycemic control, improve response to drugs (including insulin therapy), reduce the frequency of treatment-related hypoglycemia and / or reduce complications. Therefore, the restoration of β-cell function will be clinically useful. Simply put, patients with higher β-cell function can have excellent results, and the less endogenous insulin a patient secretes (even with insulin therapy), the less likely the patient will achieve treatment goals and glycemic stability.
[0159] The relief (or at least reduction) of glucose toxicity and the recovery of beta cell function have been demonstrated in newly diagnosed diabetes. For example, a study reported that the two-week intensive insulin therapy applied to patients with new-onset diabetes and acute ketoacidosis reduced blood glucose levels to the extent that after another four weeks, it induced frequent hypoglycemia. The insulin dose was rapidly reduced, and insulin was discontinued after two weeks. During the three-month follow-up, the patient's A1C value was 6.8%. Therefore, it is reported that this short-term intensive insulin regimen relieved glucose toxicity and restored beta cell function. (J. Mayfield, et al., Insulin Therapy for Type 2 Diabetes: Rescue, Augmentation, and Replacement of Beta-Cell Function, American Family Physician 70: 3: E489-501 (August 1, 2004). However, in patients with longer time periods or in late diabetic patients, the relief of glucose toxicity and the recovery of beta cell function have not been demonstrated before.
[0160] Clinical data indicate that maintaining blood glucose balance over time according to the disclosed systems, devices and methods can alleviate glucose toxicity and restore pancreatic beta cell function. The term "sustained blood glucose balance" as used herein with respect to certain embodiments refers to achieving blood glucose balance and / or improved GCI over a period of more than about three months as disclosed herein.
[0161] As known in the art, the standard of insulin healthcare therapy is usually no more than 250 insulin units (IU) per day. The traditional reason for not exceeding this dosage is that it has the risk of causing dangerous hypoglycemia. As used herein for certain embodiments, the term "high insulin dosage" refers to an insulin dosage of more than about 250 IU per day for one or more days.
[0162] While use of the systems, devices, and methods disclosed herein, including use of the systems, devices, and methods by medical professionals trained in accordance with the systems, devices, and methods disclosed herein, it has been found that achieving sustained blood glucose balance can alleviate (or at least reduce) glucose toxicity and restore (or partially restore) beta cell function, as clinically demonstrated by reducing the dose of insulin required to maintain blood glucose levels.
[0163] For example, Fig.37As shown in, the exemplary system was used for a patient over a period of 9 months. The method initially resulted in a significant increase in insulin dosage. The change in insulin dosage from 240 units / day to more than 400 units / day during the first 4 months moved the blood glucose level of the subject into the normal range during the subsequent 5 months. The patient's A1C was 12.5% at baseline and 6.6% after 4 months of use. Over the next 5 months, blood glucose levels were maintained in a near-normal range while reducing insulin dosage back to approximately 240 units / day. In the case of a higher residual β cell function, the patient required less insulin to achieve the same therapeutic outcome, demonstrating the alleviation of glucose toxicity and the recovery of β cell function.
[0164] like Fig.38 As shown in, exemplary system is used for another patient for more than 15 months. The blood glucose curve of this patient shows nearly 3 times increase of insulin (from 150 units in April 2013 to 400 units in April 2014) in a whole year, and blood glucose level is reduced to optimal range (from 425mg / dl in April 2013 to 180mg / dl in August 2013) in 4 months. Maintaining blood glucose level in optimal range eventually leads to the gradual reduction of required insulin amount. During the following three months (from April 2014 to June 2014), the dosage of insulin required for maintaining blood glucose balance is almost reduced by half (from 400IU / day to about 200IU / day). In the case where residual β cell function is higher, this patient needs less insulin to achieve the same therapeutic result, proving the alleviation of glucose toxicity and the recovery of β cell function.
[0165] like Fig.39 In the embodiment of the present invention, the exemplary system is used for another patient for more than 10 months. The blood glucose curve of this patient shows the reduction of insulin between the first 4 months (from 415 units / day in March 2013 to 240 units / day in July 2013), and the blood glucose level remains in the optimal range. The blood glucose level is maintained in the optimal range and the reduction of the required amount of insulin is caused. In addition, in the same time period, the frequency of hypoglycemic events (for example, glucose measurement values below 4mmol / L) is reduced. In the subsequent 6 months (from July 2013 to December 2013), the insulin dosage required for keeping blood sugar balance is maintained at 240-270 units / day (significantly reduced compared with the earlier dosage of 415 units / day) almost unchanged. In the case where the residual β cell function is higher, this patient needs less insulin to achieve the same therapeutic results, which proves the alleviation of glucose toxicity and the recovery of β cell function.
[0166] These cases illustrate that the use of the systems, devices and methods disclosed herein provides a protective aspect to diabetes treatment by continuously assessing insulin requirements and increasing or decreasing the dose as needed. This aspect is particularly important for patients who partially restore endogenous insulin secretion, because over time, they require significantly less exogenous insulin to maintain blood sugar balance and prevent dangerous hyperglycemia.
[0167] Hypoglycemic events
[0168] Correctly interpreting hypoglycemic events for the purpose of insulin regulation, it is useful to appropriately mark such events. In general, non-fasting glucose levels reflect previous insulin injections. For example, lunch glucose readings reflect the impact that breakfast insulin boluses may have on the user's blood glucose level. In some cases, as a non-limiting example, when users feel symptoms of hypoglycemia, they can measure glucose outside their regular schedule. Such glucose data points are usually marked as 'others'. If the 'other' glucose level is low, it is very useful to confirm the insulin injection that is most likely to cause the 'other' low blood glucose level, so that the appropriate insulin dosage component will be reduced accordingly. The process of reclassifying 'other' events depends on the timestamp of the 'other' event and the time elapsed from the previous event (such as a meal event) that is not classified as 'other'. The pharmacokinetic characteristics of the specific insulin used by the user can help set the time window, during which injection may have a specific effect that causes low blood glucose levels. In one embodiment, the user can administer a rapid-acting insulin that can be effective 30 minutes after injection and whose effect will completely disappear within 6 hours after injection. For this embodiment, if the 'lunch' event is recorded at 12 noon and the low blood glucose level is recorded as 'other' at 12:10 p.m., this low blood glucose level can not be the result of the lunch rapid-acting insulin injection, because it occurs too quickly, and the rapid-acting insulin needs a long time to start affecting the blood glucose level. Similarly, if the 'other' event is recorded after 6 p.m., this can not be the reason for the lunch rapid-acting injection, because its effect has been lost for the user. Therefore, it is understandable that for rapid-acting insulin, according to the pharmacokinetic activity curve of 30 minutes to 6 hours from the injection, the low blood glucose level marked as 'other' that occurs within 30 minutes to 6 hours from the injection event is likely to be the result of the injection. Therefore, it may be expected to reduce the dosage component that is most likely to cause this low blood glucose level.
[0169] Other types of insulin can also be considered. Some fast-acting or ultra-fast-acting insulins can have a pharmacokinetic activity curve in which they begin to affect blood glucose levels within 15 minutes of administration and the effect gradually disappears within 3 hours. Older types of insulin, such as Regular Insulin (produced by Eli Lilly), may take 45 minutes to begin to affect blood glucose levels and take up to 8 hours to gradually disappear. If the user administers premixed or biphasic insulin, the pharmacokinetic curve of such drugs, such as Humulin 70 / 30, Novolin 70 / 30, Humalog Mixed 75 / 25 or Novo Nordisk Mixed 70 / 30, may affect blood glucose levels, starting at about 1 hour after injection and ending at about 12 hours after injection. It is also understood that long-acting insulins, such as or There are fairly flat pharmacokinetic curves and their activity levels are nearly constant over a 24 hour period. Therefore, if a user administers a combination of long-acting and rapid-acting insulins for their diabetes management, the glucose levels marked as 'other' that fall outside a specific time window after rapid-acting insulin administration are most likely due to background long-acting insulin injections. Therefore, if an 'other' event records a low glucose level and occurs 7 hours after the last meal event recorded in the history, that glucose level can be used to reduce the long-acting insulin dosage component.
[0170] In certain embodiments, it may be desirable to reduce insulin dosage components once very low blood glucose (VLG) levels are recorded in the history. VLG levels can be defined as blood glucose levels below 60 mg / dl, although other numbers, such as below 70, 65, 55, 50, 45, 40 or 35 mg / dl and other numbers within similar ranges may also be used. Once VLG has been recorded, it is desirable to reduce the dosage components that are most likely to cause the VLG. The dosage component may be reduced by a ratio of 10%, 20%, 30%, 40% or 50%, or by a fixed number of insulin units, such as by reducing 1, 2, 3, 4, 6, 8, 10 or other reasonable numbers within the range. The reduction in dosage may also be a combination of the two, such as a dosage component that will reduce the larger of (X units or Y%). In this case, if the user administers 10 insulin units, such as X=2 and Y=10%, then the greater of 2 [insulin units] or 10% of 10 insulin units is 2 [insulin units], in which case the new dose composition will be 8 insulin units, instead of the previous composition of 10. In other cases, the combination can be the smaller of (X units or Y%). If the latter is applied to the previous example, then the smaller of the two is 1 insulin unit and the new recommended dose composition will be 9 insulin units, instead of the previous composition of 10. Another option for dose composition reduction is 'recalculation', that is, finding the previous dose composition lower than the current dose composition and replacing the current one with the previous one. For example, if the insulin dose composition is 10 units and is later increased to 13 units. And, after a while, the dose composition of 13 is suspected to be the reason behind the VLG, it may be desirable to replace the composition 13 with the previous lower value of 10. It does not matter whether it is done proportionally or with fixed minimum / maximum reduction values, because according to the data in the device history, the previous value of 10 did not cause any VLG.
[0171] In some cases, it will be appreciated that glucose values can be low but not very low. The scope of low glucose LG can be defined as previously considered, non-VLG but lower than a specific value (like 75mg / dl). Other numbers can also be used for upper threshold limits, like 90,85,80,70,65,60,55,50,45 or 40mg / dl or other reasonable numbers within the scope. In some embodiments, it may be desirable to explain multiple LG values, even if there is no value in them independently as the VLG of the updated insulin dosage component. If similar events are suspected to cause LG values, this will be particularly useful. For example, if the dosage is settled on Monday evening and the Tuesday lunch LG value is recorded and the Wednesday lunch LG value is recorded, it may be desirable to reduce the breakfast dosage component. Another embodiment may be that 3 LG values have been recorded for different events within a 24-hour cycle. Also another embodiment may be that 4 LG values have been recorded for different events since the time when the last dosage was settled. Other combinations are also contemplated, such as 3 or more LG values for a specific event; 2 LG values or more within a 24 hour period; or 2, 3, 4, 5, 6, 7, 8, 9, 10 LG values recorded from the timestamp when the current dose was administered.
[0172] It is understandable that low blood glucose values usually indicate that the user is applying too much insulin in terms of its current metabolic state. This situation may cause VLG or potentially life-threatening severe hypoglycemia events. Therefore, it is expected that the system for adjusting insulin dosage can reduce one or more of the user's insulin dosage components to try to prevent the situation from having negative clinical consequences. The above-mentioned behavior of the system for adjusting insulin dosage on a synchronous basis (such as once a week) can be summarized as follows: if the system has recorded one or more VLG values, efforts will be made to identify the dosage components that may have caused the one or more VLG values and reduce them according to the dosage reduction rule. This response occurring for one or more VLG values may or may not reset the synchronous time base in the insulin regulation process. If the system has recorded one or more LG values, attempts will be made to evaluate the cause of the one or more LG values and respond accordingly by reducing one or more of the insulin dosage components. This reduction may or may not result in the resetting of the synchronous clock.
[0173] Insulin regulation
[0174] When adjusting insulin dose, it may be desirable to prevent oscillations (i.e., low blood glucose levels leading to dose reductions, leading to higher blood glucose levels, leading to dose increases, leading to lower blood glucose levels, etc.). Several mechanisms may be used to dampen, reduce or substantially reduce erratic dose oscillations. One such mechanism would be to insert 'off intervals' between different directions of dose adjustment. For example, the system may follow a rule that if the dose is reduced from baseline, then the next dose adjustment step may be a further reduction or standstill rather than an increase. In this way, dose increases will generally not be followed by dose reductions, thereby reducing the likelihood of blood glucose level oscillations. Another mechanism may be that if a dose reduction occurs and an increase is suggested in the following dose adjustment step, then such an increase should generally be limited to an intermittent value. The increase may be limited to less than a particular level, for example, less than the value used before the reduction occurred; or not higher than the level used before the reduction occurred; or not more than 5%, 10%, 15% or 20% or 2 insulin units or 4 insulin units of the level used before the reduction occurred; or other similar expressions. Thus, it can be appreciated that the insulin dosage adjustment system uses short-term memory not only by reviewing the blood glucose data accumulated in the review period history, but also by employing the dosage history prior to the review period.
[0175] It will be appreciated that a similar mechanism can be used for the other direction, i.e., a dose reduction followed by an increase. Such a reduction can also be limited, suppressed, reduced, prevented, or substantially prevented from unstable oscillations. However, it will be appreciated that insulin dose reductions are usually performed to improve the safety of treatment and to prevent future hypoglycemia.
[0176] In some embodiments, it is desirable to prevent continuous dose increments because the user response to such increments may be delayed. Delayed responses to insulin dose increments may result in severe hypoglycemia or other adverse events. In some embodiments, the envisioned system may use continuous dose increment rules to create a 'downtime period' if an excessive number of continuous dose increments occur. For example, the system may employ a rule that prevents 2 continuous increments from occurring (i.e., creates a 'downtime period' after each dose increment, allowing delayed responses). Other rules may also be applied, for example, allowing two continuous dose increments instead of 3; or allowing 3 continuous dose increments instead of 4; or allowing 4 continuous increments instead of 5. In certain embodiments, the maximum number of continuous increases may be limited to 3, 4, 5, 6, 7, or 8.
[0177] When considering that the number of continuous increments of insulin dosage is limited, the problem of what constitutes the increase of insulin dosage may occur. For users of only basal insulin, it is nothing more than the daily total amount of insulin that is larger than previously taken. However, for patients of premixed insulin or basis-bolus therapy, the determination of whether increase has occurred may be more complicated. For example, if the object has taken 20 units of premixed insulin during breakfast and 30 units during dinner, and the blood glucose value of the object rises before dinner, but becomes low before breakfast, the reasonable regulation of insulin dosage can then be to take 22 units during breakfast and 27 units during dinner, and this regulation is to constitute the increase of insulin dosage or reduce and may not be clear. Similarly, the user of basis-bolus insulin therapy can take 10 units of rapid-acting insulin with every meal, and the correction factor is to add one unit of insulin per 30mg / dl of the glucose that rises higher than 120mg / dl, and the bedtime dosage of 30 units of long-acting insulin. Glucose levels over a period of time may indicate that it is appropriate to increase the breakfast dose from 10 units to 12 units, decrease the lunch dose from 10 units to 9 units, decrease the dinner dose from 10 units to 8 units, and increase the bedtime dose from 30 units to 35 units. Likewise, it is not necessarily clear whether a new dose constitutes an increase over a previous dose.
[0178] The method for checking whether insulin dosage has increased can be based on the daily total amount of insulin.For example, for the situation of above-mentioned premixed insulin, the daily total amount of insulin is 50 units (20 during breakfast and 30 during dinner) and the daily total amount of new dosage of insulin is 49 (22 during breakfast and 27 during dinner).Therefore, new dosage will not be considered to increase.For above-mentioned basis-bolus embodiment, the initial daily total amount will be 60 units (3x10+30) and the new daily total amount is 64, therefore will be ruled as increase.
[0179] Another way to determine whether an insulin dose has been increased is if any component of the dose is greater than the same component of the previous dose. Using this approach, in the above two examples, the change would be considered an increase. That is, premixed insulin, because the breakfast dose is increased from 20 units to 22 units, and basal-bolus insulin, because the breakfast dose is increased from 10 units to 12 units, and bedtime from 30 units to 35 units.
[0180] Another method of determining whether the insulin dose has been increased can be by a "majority vote" rule, where a majority of the dose components have to be increased to determine that the dose has been increased compared to the previous period. According to the majority vote rule, none of the previous embodiments would be considered an increase. That is, the premixed insulin embodiment has one-half of the components increased, and the basal-bolus embodiment has two-quarters of the components increased, and none of them constitutes a majority.
[0181] Therefore, there are several methods that can be used to assess whether a new dose represents an increment compared to a previous dose. Some embodiments are provided in Table 1 below. This can be simple for a basal insulin regimen in which a user has to apply only Z1 insulin units every day. Then, if the new dosage component Z2 is greater than Z1, the dosage has increased. However, for more complex regimens, such as premixed / biphasic insulin therapy or basal bolus insulin therapy, alternative definitions can be used to define what constitutes a dose increase. For example, for a premixed / biphasic insulin regimen, each dosage component is only the dosage that a person needs to apply for a given event. That is, a premixed insulin dose can include an insulin dose of X1 units during breakfast and a dosage of Y1 units during dinner. If the new dosage includes X2 and Y2, several methods can be used to determine the increment, such as the method shown in Table 1 below:
[0182] <![CDATA[X2+Y2>X1+Y1]]> <![CDATA[X2>X1 and +Y2≥Y1]]> <![CDATA[Y2>Y1 and +X2≥X1]]> <![CDATA[X2 > X1 and +Y2 < Y1 but X2 + Y2 > X1 + Y1]]> <![CDATA[Y2 > Y1 and +X2 < X1 but X2 + Y2 > X1 + Y1]]> <![CDATA[X2>X1 or Y2>Y1]]>
[0183] Table 1
[0184] In addition, in some embodiments, the projected daily total (such as the sum of the dosage components) can be used to determine whether the current insulin dose represents an increase compared to the previous week. In the scheme that requires carbohydrate counting, the projected daily total will need to estimate the average meal size because the dosage components are ratios and cannot be simply added to determine the daily total. The meal size estimation can rely on the recorded carbohydrate intake entered in the system within a predetermined time period, such as last week, the past few weeks or the last month. The estimated meal content can be calculated for different meals or as the daily total of recorded carbohydrate intake.
[0185] In some embodiments, the historical data stored in the system memory may be incomplete. In some embodiments, incomplete data may be defined as being less than 3 data points for a specific event. In other embodiments, incomplete data may be defined as being less than 5, 4, 2 or 1 data points for each event. In some cases, the user may choose to only measure fasting blood glucose. This has the meaning of varying degrees because of the difference in the insulin regimen used by the user. If the user follows only the basic regimen, the fasting blood glucose level may be enough to safely and effectively regulate insulin dosage to achieve better blood sugar balance. However, for people who use premixed insulin therapy, who administer insulin twice a day, a single test every day may not be enough to properly regulate insulin.
[0186] In some embodiments, for example, the incomplete situation of a specific data set (such as ' breakfast ' type event) is referred to as a missing data set. If there is a missing data set, the system can decide to keep the insulin dosage constant. In other embodiments, the existence of the missing data set may be the reason for the allowed variation of other dosage components. For basic-bolus insulin therapy, the existence of the missing data set can be used to limit the ratio between quick-acting and long-acting insulin. In other embodiments, it may be desirable to limit the increase allowed by a single quick-acting insulin dosage component.
[0187] Using methods to prevent continuous increases or erratic increases (oscillations) in insulin dosage may result in better prognosis with potentially better outcomes over longer periods of time. Fig.37 The embodiment shown in shows how the above method can be used to constrain the rate of increase of insulin dosage during the initial treatment phase, and despite the increase in glucose levels, insulin increases were stopped on 11 / 23 / 12 and 1 / 17 / 13. Similarly, on 4 / 5 / 13, the daily total amount of insulin was 349 units, which was reduced to 332 units in the following period, and then increased, but only to 343 units, to prevent unstable oscillations of dosage. The combination of the proposed methods produces the ability to bring glucose levels into the desired range and keep them within the desired range for 6 months.
[0188] Balance Point
[0189] Clinical data may indicate that the optimal balance point is different for different people with diabetes. For example, in some studies, it has been noted that a small portion of the study population (approximately 10% of subjects) experienced approximately 90% of severe hypoglycemic episodes. It is likely that some people with diabetes are more susceptible to hypoglycemia. For such individuals, the optimal blood sugar balance may represent A1C>7%, as an A1C of 7% or less would put them at greater risk.
[0190] Each individual's optimal blood glucose balance may change over time and may not have a 'stable state'. That is, each individual's optimal GCI may need to be continually evaluated. One reason for this may be that the GCI may be affected by the variability of the individual's glucose data. For some, this variability is low, such as Fig.13 as shown in . Fig.13 Patients with low variability in glucose levels are shown. Each point in the graph represents the average glucose data for each week and the vertical bars are plus or minus one standard deviation. For others, the variability is high, such as Fig.14 as shown in . Fig.14 Patients with high variability in glucose levels are shown. Each point in the graph represents the average glucose data for each week and the vertical bars are plus or minus one standard deviation. For others, the variability may not be consistent, such as Fig.15 as shown in . Fig.15 Patients with varying levels of glycemic variability are shown. Each point of the figure represents weekly average glucose data and the vertical bar is plus or minus one standard deviation. In weeks 10-16, there are many more blood glucose values <65 mg / dl (numbers below each line) compared to weeks 1-9, despite the fact that average glucose is roughly stable and actually slightly higher during the second period.
[0191] In general, in certain embodiments, applying a quality policy of optimizing GCI may be safer than applying a policy aimed at reducing A1C. Neglecting to set treatment goals that account for hypoglycemia may lead to serious consequences, even death. However, by applying a policy of optimizing blood glucose balance or GCI, as shown in certain embodiments, one can be assured that as long as the treatment does not result in excessive hypoglycemic episodes, it will only be intensified.
[0192] There is no consensus on what constitutes mild hypoglycemia. It is generally accepted that severe hypoglycemia is hypoglycemia that requires assistance from a third party to resolve. It is also accepted that mild hypoglycemia may be the best predictor of severe hypoglycemia. However, while some define mild hypoglycemia as a capillary glucose level of less than 70 mg / dl, amounts such as 65, 50, or even 40 mg / dl may also be found.
[0193] Implementation of subjects with high glucose levels and low variability e.g. Fig.16 and 17 Shown in. Fig.16 It is shown that during the entire 16-week period, the patient had only one glucose level < 65 mg / dl (week 15). Fig.17 The study showed that total daily insulin more than doubled over 12 weeks (120 to 270 [IU]). This particular subject could safely maintain an A1C level of 6.1%, well below the recommended target of 7%.
[0194] Implementation of objects with low glucose, high variability e.g. Fig.18 and 19 as shown in . Fig.18 It is shown that during the first 4 weeks (run-in period), the subject had 3 hypoglycemic episodes per week (rate of 156 episodes / year), and during the last 4 weeks, the subject had 4 hypoglycemic episodes, a rate of 52 / year. Fig.19 It was shown that rather than decreasing, insulin increased from -80 units per day to nearly 140 units per day throughout the intervention period.
[0195] One embodiment of a subject with low blood sugar, low variability is e.g. Fig. 20 and 21 as shown in . Fig. 20 The subject is shown to have a Week 4 A1C of 7.7%, with mean glucose below 150 mg / dl, but had 6 hypoglycemic episodes during the run-in period. Fig.21 It was shown that total daily insulin remained fairly stable at -180 units for this subject, but its distribution shifted from a 45% / 55% basal to bolus ratio in week 4 to a 30% / / 70% basal to bolus ratio in week 16.
[0196] One embodiment of an object with high glucose, high variability is Fig. 22 and 23 as shown in . Fig. 22 It is shown that for this subject, the hypoglycemia rate decreased from 182 / year to 48 / year, while the A1C increased from 8.2% (week 4) to 9.7% (week 16). Fig.23 Relative to the previous 3 embodiments, it is shown that the subject counts carbohydrates to figure out his bolus dose. Therefore, the dietary dose is given in proportion. For example, the dinner dose starts with a ratio of 1 [IU] to every 15 grams of carbohydrates and ends with a ratio of 1 [IU] to every 9 grams of carbohydrates. In order to reduce hypoglycemia, the basal dose is reduced from 25 [IU] to 12 [IU] (the 4th to 8th week). Thereafter, in the absence of hypoglycemia, the insulin dose is slowly increased. Finally, the subject takes insulin with almost the same amount as at the beginning but with a far different distribution at the end of the study.
[0197] Implementation of premixed insulin therapy in patients Fig.24 and 25 as shown in . Fig.24showed an 'unexplained' decrease in weekly mean glucose from weeks 1 to 4 as insulin dose remained constant over this time period, then an increase in insulin dose (from 92 units to 140 units total daily) in weeks 5-8 resulted in a significant increase in mean glucose (from ∼230 mg / dl to ∼300 mg / dl), and then mean glucose in weeks 12-14 was approximately equal to that in week 5, despite insulin doses of ∼190 units per day (more than double that in week 5). Fig.25 This is illustrated by the fact that certain disclosed embodiments do not allow for dose increases beyond 4 consecutive weeks. Note that despite the increase in glucose levels, there were no dose increases in weeks 9 and 13.
[0198] Fig.26 and Fig. 27 It is shown that certain disclosed embodiments have the ability to independently adjust different dosage components for a patient on premix therapy. The patient experienced some hypoglycemia throughout the day at weeks 6-9 and 12-16, to which the embodiment responded by reducing the breakfast dosage component while still being able to increase the dinner component. The patient had an A1C of 9.1% at week 0, 8% at week 4, and 5.8% at week 16.
[0199] Fig.28 A patient is shown taking a relatively small daily total of -45 units / day, almost equally divided between basal and bolus. The average glucose for this patient during the run-in period was just below 150 mg / dl, and the A1C was 9% at week 0 and 8.4% at week 4. Certain embodiments are able to further improve glycemic balance by slowly increasing the independent bolus dosage component to a final daily total of -57 units / day. The A1C at week 16 was raised to 7.4%, with only two hypoglycemic episodes (once per week) in the last two weeks. Fig.29 Basal insulin was shown to start at 24 and end at 255 units / day, peaking at 28 units / day in weeks 14-15. At the same time: breakfast doses from 6 to 9 (+50%), lunch doses from 6 to 11 (+83%), and dinner doses from 8 to 11 (+37%). While the bolus dose increase may seem drastic, it was achieved in a safe manner with acceptable hypoglycemia rates and well-improved A1C.
[0200] These examples illustrate that in certain embodiments, the goal of diabetes management can be to achieve glycemic balance or an improved glycemic composite index that weights both A1C and hypoglycemia.
[0201] Certain embodiments of the present disclosure are directed to systems, methods and / or devices for treating diabetes in a patient by providing treatment guidance based on whether and by how much to change at least one of the one or more components of the patient's current insulin dosage regimen to more closely approximate the patient's desired glycemic balance point.
[0202] Certain embodiments of the present disclosure relate to systems, methods and / or devices for treating diabetes in a patient by providing treatment guidance based on whether and to what extent to change at least one of the one or more components of the patient's current insulin dosage regimen to more closely approximate the patient's desired glycemic balance point and individual treatment goals over time.
[0203] Certain embodiments of the present disclosure relate to systems, methods, and / or devices for treating diabetes in a patient by providing treatment guidance designed to slowly and / or safely guide its user to better glycemic balance.
[0204] Certain embodiments are directed to providing guidance to each individual subject on a dynamic basis to move that subject toward proper glycemic balance.
[0205] In certain embodiments, providing treatment guidance for diabetes treatment in a patient by utilizing blood glucose balance may entail one or more of the following:
[0206] a) lowering average blood sugar increases the chance of experiencing hypoglycemia;
[0207] b) hypoglycemia constitutes a potential risk to the patient and, under certain conditions, this should lead to timely dose adjustments (regardless of time intervals);
[0208] c) A single severe hypoglycemic event may be an insignificant event, in that it requires immediate attention but does not reset the synchronized clock;
[0209] d) the event may not need to be re-counted, in other words, if the dosage component is adjusted in response to (c), that particular severe hypoglycemia data point will generally be ignored and not used again when concurrent evaluation of the data occurs; and / or
[0210] e) The dose assessment method should generally reflect the current dose. That is, when an asynchronous, full dose adjustment occurs (due to an excessive number of hypoglycemic events since the last full update), the synchronous clock will be reset and the hypoglycemic event that caused the asynchronous full dose adjustment will expire.
[0211] As a result, some embodiments use windows of varying lengths that include events that occurred after the last update, but no more than 7 days (this is done to allow events to expire based on the time when there are not enough events in the history to adjust the dosage). Other time periods may also be used, such as 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13 or 14 days. Some embodiments may perform at least two types of updates: partial and full.
[0212] Partial update can be triggered by severe hypoglycemia event and immediately adjust (reduce) the dosage component that must have caused severe low amount. This does not need to reset the clock and can be treated as irrelevant until there is more evidence that this is not irrelevant (that is, there are more hypoglycemia attacks). In some embodiments, partial update is triggered only by severe hypoglycemia attack. In some embodiments, any low blood glucose value, the low value below a specific threshold, can cause partial or complete update of insulin dosage. In some embodiments, two or more low blood glucose levels can cause complete update. In some embodiments, 1 severe hypoglycemia attack and two low blood glucose levels can cause complete update. In other embodiments, low blood glucose values may only cause partial update. In some embodiments, two or more low blood glucose values of each event can cause complete update. In other embodiments, low blood glucose values greater than 3,4 or 5 can cause complete update.
[0213] The complete update uses the available data in the effective history (e.g., earlier than the last dose update and no more than 7 days) to adjust one or more dosage components. In certain embodiments, the complete update will adjust all dosage components. In other embodiments, the complete update will adjust one or more dosage components. Other time periods can also be used, such as 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13 or 14 days. It is assumed that this data set reflects the latest efficacy of the active dose. In certain embodiments, the complete update resets the synchronous clock, thereby causing the event as part of this dose adjustment to expire by becoming older than the most recent dose timestamp. In certain embodiments, the complete update resets the synchronous clock, thereby causing a considerable portion of the event as part of this dose adjustment to expire by becoming older than the most recent dose timestamp. In certain embodiments, the complete update resets the synchronous clock, thereby causing all events as part of this dose adjustment to expire by becoming older than the most recent dose timestamp. In certain embodiments, the complete update resets the synchronous clock, thereby causing a portion of the event as part of this dose adjustment to expire by becoming older than the most recent dose timestamp.
[0214] In certain embodiments, a full update may be triggered by time, by a determination that the frequency of hypoglycemia exceeds a certain limit, or by a combination thereof. A full update may also be triggered by external intervention, such as by a treating clinician or by the introduction of additional knowledge that may affect the user's metabolic state. Such knowledge may be that the user has started or stopped other medications; or the progression of a physiological condition, such as a temporal illness, such as the flu; or a condition like end-stage renal failure. Other examples that may trigger a full update are a visit to the emergency room, any type of trauma, or other medical condition that would cause a person with knowledge in the art to reset the insulin dose or regimen, or both.
[0215] In some embodiments, a complete update can be triggered by time (e.g., 7 days have passed since the last update). In this case, each data set is evaluated for integrity. Some embodiments require at least 3 data points for each event. If a certain event has less than 3 data points, it is declared as missing data. If the data of an event is missing, certain safety measures are applied to ensure that the remaining dosage components will not change too actively. For example, if more than 1 data set is missing, it can be decided not to adjust the dosage.
[0216] In some embodiments, a full update may also be triggered by a determination that the frequency of hypoglycemia exceeds a certain limit. In this case, it is likely that there are less than 3 data points per event. Nevertheless, since a full update is triggered, some embodiments use whatever data is available in memory for safety reasons.
[0217] The logic behind certain embodiments is that a) you must let the dose settle; and b) if a full update occurs, then events (including lows) must be due, otherwise certain embodiments will interpret events that do not reflect the efficacy of the current dose (i.e., a hypoglycemic episode that occurred before the active dose was placed).
[0218] In certain embodiments, one or more of the following may be combined:
[0219] 1) Insulin dose increases can be made at a more gradual pace. For example, certain embodiments may not allow for more than 3, 4, 5, or 6 consecutive insulin dose increases. This results in slower dose increases that can have a longer-term effect: for example, if a subject starts with 50 units per day and averages glucose levels over 200 seconds, their dose can be increased by 20% to 25% for several weeks, leading them to a daily total of about 100 units in 4 weeks. Although each change is small, the cumulative effect may take time to set in. As in Fig.16 and 17 Among the subjects shown in , mean glucose decreased significantly at weeks 9 and 13, despite insulin doses remaining the same from the previous week.
[0220] 2) Hypoglycemia is an inherent part of insulin therapy. Unless it is considered active dose, there is no need to respond to it either aggressively or conservatively.
[0221] 3) Limited correlation between events. Certain embodiments treat each event group independently. In some embodiments, correlation between events is only considered when data is missing.
[0222] 4) Certain embodiments attempt to prevent unstable oscillations by limiting an increase following a decrease to not exceed the level that caused the preceding decrease.
[0223] In certain embodiments, the glycemic index (GI) may be defined as the minimum of the mean and median values of a particular data set (e.g., historical blood glucose levels during an assessment period labeled 'lunch'). For a regimen of basal-bolus insulin therapy, the GI may then be used to adjust the breakfast dose component in the AIDF according to the following Table 2, where Δ is a number of insulin units to be added to the current breakfast dose component:
[0224]
[0225] Table 2
[0226] Wherein, for certain embodiments, MAX is the maximum; INT_MIN is the minimum integer within a given range; and BD(k) refers to the breakfast dose component within the valid IDF. Other ranges may also be used in the left-hand column. For example, the GI range may be 0-60, 61-70, 71-120, 121-180, 181-230, 231-280, and above 281. Other embodiments are also valid. It will be understood that if the patient is using a fixed breakfast bolus dose of 10 units and GI=140, then the new breakfast dose component is adjusted to 11 units. At the same time, if the patient is using a breakfast carbohydrate to insulin ratio of 1 insulin unit to 10 grams of carbohydrates, then according to the right-hand column, the new dose component will be a ratio of 1 [IU]:9 [grams of carbohydrates].
[0227] In certain embodiments, different tables can be used to adjust different dosage components. For example, although the breakfast dosage component can be adjusted according to the examples given above, certain embodiments can use the following table 3 to adjust the dinner dosage component.
[0228]
[0229] Table 3
[0230] where DD(k) refers to the evening dose component of AIDF.
[0231] In certain embodiments, there is another table that can be used to adjust the long-acting insulin dosage component. For example, although the breakfast dosage component or the dinner dosage component can be adjusted according to the above embodiment, certain embodiments can use the following
[0232] Table 4 shows adjustments of long-acting dose components based on breakfast glucose data.
[0233] GI Δ 0-50 -MAX(1,INT_MIN[0.1*LD(k),0.2*LD(k)]) 51-100 -MAX(1,INT_MIN[0.05*LD(k),0.1*LD(k)]) 101-135 0 136-200 MAX(1,INT_MIN[0.05*LD(k),0.1*LD(k)]) 201-250 MAX(1,INT_MIN[0.1*LD(k),0.2*LD(k)]) 251-300 MAX(1,INT_MIN[0.15*LD(k),0.25*LD(k)]) 301+ MAX(1,INT_MIN[0.2*LD(k),0.3*LD(k)])
[0234] Table 4
[0235] Managing diabetic patients
[0236] In certain embodiments, it is desirable to enable a group of people with insulin-treated diabetes to better manage their blood sugar levels. Such embodiments can be used to significantly reduce the cost of health care. For example, it is well documented that high hemoglobin A1C is a contributing factor to a significantly higher probability of suffering from complications related to diabetes. Studies have shown that reducing a patient's A1C from 9% to 7% reduces the chance of suffering from retinopathy by about 76%. Since nearly 80% of medical expenses are due to hospitalization, readmission or emergency room visits, it is very useful to reduce the average A1C within the group as a tool to reduce the cost of health care. It is also useful not to reduce A1C below a certain threshold, because low A1C has been shown to be a high risk factor for severe hypoglycemia. Because hypoglycemia is the main reason for emergency room visits for people with insulin-treated diabetes, it is very useful to reduce the hypoglycemia rate of a given group as a way to reduce the overall cost of health care.
[0237] In certain embodiments, it is desirable to enroll a patient population service that modulates insulin dosage as a way to improve diabetes outcomes by reducing A1C and / or hypoglycemia rates, leading to reduced health care costs. For example, a group of patients aged 21-70 years who have a clinical diagnosis of type 1 or type 2 diabetes for at least one year are enrolled. In this example, if a patient has a body mass index (BMI) ≥ 45 kg / m 2 ; severely impaired cardiac, hepatic, or renal function; psychological or cognitive impairment; more than two episodes of severe hypoglycemia in the past year; or a history of hypoglycemia unawareness, then they could be excluded. Eligible patients could be enrolled in one of three treatment groups, which included patients with: I. suboptimally controlled type 1 diabetes (A1C ≥ 7.4%) treated with basal-bolus insulin therapy that could be combined with carbohydrate counting; II. suboptimally controlled type 2 diabetes (A1C ≥ 7.4%) treated with basal-bolus insulin therapy (without carbohydrate counting); and III. suboptimally controlled type 2 diabetes (A1C ≥ 7.8%) treated with twice-daily biphasic insulin.
[0238] In this example, it is useful to use the first 4 weeks as a baseline and allow patients to continue their pre-registration regimen without intervention. Over the next 12 weeks, the self-measured blood glucose readings reported in the patient's diary can be processed weekly by certain embodiments that suggest new insulin doses. Although generally encouraged to follow the recommended doses, patients are allowed to deviate from the prescribed doses during unusual circumstances (such as expected physical activity). Patients in Groups I and II are asked to test and record their capillary glucose 4 times a day before meals and before bedtime and patients in Group III are asked to test twice a day before breakfast and dinner. All patients may be asked to measure capillary glucose at night every 5-9 days. The information captured in the diary includes time-stamped regular and irregular glucose readings, insulin doses, and carbohydrate amounts (Group I only). Reductions in health care costs are measured by improved efficacy: defined in this example as improvements in self-measured weekly average glucose, and reductions in A1C; and, by improved safety, defined as a reduction in the frequency of hypoglycemia in patients with high hypoglycemia rates (e.g., more than 3 events per week), and maintaining hypoglycemia rates at acceptable levels for others, such as no more than one event per week. In this example, hypoglycemia was defined as blood glucose < 65 mg / dl.
[0239] Using certain disclosed embodiments, a group of patients may be treated to improve diabetes management and reduce healthcare costs by providing them with a device that replaces their blood glucose meters and automatically uses multiple historical glucose data to adjust insulin therapy so that the group achieves a better glycemic balance point.
[0240] In this example, use of certain disclosed embodiments can result in significant reductions in A1C in just 12 weeks, e.g., a baseline A1C from 8.4% to 7.9%, and a reduction in weekly average glucose from a baseline of 174 mg / dl to an endpoint of 163 mg / dl. Also, for patients with a high frequency of hypoglycemia, the rate was reduced from 3.2 events per week to 1.9 events per week without increasing A1C levels in a statistically significant manner. Also, for patients without frequent hypoglycemia, A1C was reduced from a baseline of 8.5% to 7.8%, and average glucose was reduced from 182 mg / dl to 155 mg / dl without increasing the frequency of hypoglycemia from a baseline of 0.5 events per week in a statistically significant manner.
[0241] Achieving the above results results in a reduction in the number of office visits and / or patient calls to health care providers, resulting in short-term health care cost savings. In addition, maintaining the results over a period of time can result in a significant reduction in diabetes-related complications or emergency room visits, resulting in a significant reduction in health care costs.
[0242] In this embodiment, if Fig.30 As shown in , all members of the population achieved a reduction in average glucose. Using certain disclosed embodiments, such as Fig.31 and Fig.32 As shown in , members of the type 2 diabetes population can achieve significant reductions in mean glucose and hemoglobin A1C. Fig.33 As shown in , better blood glucose balance is achieved by reducing the average glucose of patients without frequent hypoglycemia while increasing the average glucose of patients with frequent hypoglycemia. Using certain disclosed embodiments, it is possible not only to reduce the number of hypoglycemic events, but also to shift their distribution so that if a hypoglycemic event occurs, it is more likely to be a higher low blood glucose level, such as above 50 mg / dl, such as Fig.34 In certain embodiments, a statistically significant reduction in the frequency of hypoglycemia is achieved without an increase in A1C, and a statistically significant reduction in A1C is achieved without an increase in the frequency of hypoglycemia, such as Fig.35 In certain embodiments, it is useful to increase the total daily insulin dose to achieve a reduction in A1C.
[0243] In certain embodiments, it is useful to achieve a reduction in the frequency of hypoglycemia by altering the allocation of insulin between different administration sites rather than reducing the total daily insulin dose, such as Fig.36 as shown in .
[0244] Certain embodiments relate to methods, systems and / or devices for treating diabetes in a patient by providing treatment guidance, wherein the frequency of hypoglycemic events is reduced without significantly reducing the total amount of insulin used by the patient. For example, a method for treating diabetes in a patient by providing treatment guidance, the method comprising: storing one or more components of the patient's insulin dosage regimen; obtaining data corresponding to blood glucose-level measurements of the patient determined at multiple times; marking each of the blood glucose-level measurements with an identifier reflecting when or why the reading was obtained; and determining the patient's current glycemic state relative to a desired balance point; and determining whether and to what extent to change at least one of the one or more components of the patient's current insulin dosage regimen to get closer to the patient's desired balance point without significantly reducing the total amount of insulin used by the patient based on at least one of the multiple data corresponding to the patient's blood glucose-level measurements; wherein the desired balance point is the patient's lowest blood glucose-level within a predetermined range that can be achieved before the frequency of hypoglycemic events increases above a predetermined threshold.
[0245] Certain embodiments relate to an apparatus for improving the health of a population of diabetic patients, wherein the frequency of hypoglycemic events is reduced without significantly reducing the total amount of insulin used by the patient. For example, an apparatus includes: a processor and a computer-readable medium coupled to the processor, which together can: (a) store one or more components of the patient's insulin dosage regimen; (b) obtain data corresponding to blood glucose-level measurements of the patient determined at multiple times; (c) tag each of the blood glucose-level measurements with an identifier reflecting when or why the reading was obtained; and (d) determine the patient's current glycemic state relative to a desired balance point; and (e) determine whether and to what extent to change at least one of the one or more components of the patient's current insulin dosage regimen to get closer to the patient's desired balance point without significantly reducing the total amount of insulin used by the patient; wherein the desired balance point is the patient's lowest blood glucose-level within a predetermined range that can be achieved before the frequency of hypoglycemic events exceeds a predetermined threshold.
[0246] Certain embodiments relate to methods, systems and / or devices for improving the health of a population of diabetic patients, wherein the frequency of hypoglycemic events is reduced without significantly reducing the total amount of insulin used by the patient. For example, a method for improving the health of a population of diabetic patients includes: identifying at least one diabetic patient; treating the at least one diabetic patient to control the patient's blood glucose level; wherein the patient's blood glucose level is controlled using a device that is capable of: (a) storing one or more components of the patient's insulin dosage regimen; (b) obtaining data corresponding to the patient's blood glucose-level measurements taken at multiple times; (c) marking each of the blood glucose-level measurements with an identifier reflecting when or why the reading was obtained; and (d) determining the patient's current glycemic state relative to a desired balance point; and (e) determining whether and to what extent to change at least one of the one or more components of the patient's current insulin dosage regimen to get closer to the patient's desired balance point without significantly reducing the total amount of insulin used by the patient based on at least one of the multiple data corresponding to the patient's blood glucose-level measurements to get closer to the patient's desired balance point without significantly reducing the total amount of insulin used by the patient; wherein the desired balance point is the patient's lowest blood glucose-level within a predetermined range that can be achieved before the frequency of hypoglycemic events exceeds a predetermined threshold. Optimizing insulin doses over time
[0247] In certain embodiments, the present disclosure includes systems, methods, and / or devices for optimizing a diabetic patient's insulin dosage regimen over time, such as between clinic visits or over a period of months or years, thereby improving diabetic control.
[0248] As used herein with respect to certain embodiments, the term "insulin dose" is intended to refer to the amount of insulin taken on any single occasion, while the term "insulin dosage regimen" is intended to refer to a set of instructions (usually defined by the patient's physician or other medical professional) that defines when and how much insulin to take in a given time period and / or under certain conditions. A conventional insulin dosage regimen includes several components, including a long-acting insulin dosage component, a plasma glucose correction factor component, and a carbohydrate ratio component. Thus, for example, an exemplary insulin dosage regimen for a patient may be as follows: 25 units of long-acting insulin before bed; 1 unit of rapid-acting insulin for every 10 grams of carbohydrates ingested; and 1 unit of rapid-acting insulin for every 20 mg / dL, whereby the patient's blood glucose reading exceeds 120 mg / dL.
[0249] refer to Figure 1 , which constitutes a generalized schematic diagram thereof, more specifically in certain exemplary embodiments, includes a device 1 having at least a first memory 10 for storing data input corresponding to at least one or more components of a patient's current insulin dosage regimen (whether including separate units of long-acting and short-acting insulin, premixed insulin, etc.) and blood-glucose-level measurements of the patient determined at multiple times; a processor 20, which is operably connected (as shown at line 11) to the at least first memory 10; and a display 30, which is operably coupled (as shown at line 31) to the processor and is operably displayed. Information corresponding to at least the patient's current insulin dosage regimen. The processor 20 is programmed to determine whether and to what extent to change at least one or one or more components of the patient's current insulin dosage regimen based on at least the data input corresponding to the patient's blood-glucose-level measurements determined at multiple times. Such a change, if made, results in a modification of the patient's current insulin dosage regimen data stored in the memory 10, as further described herein. Thus, the data inputs corresponding to the one or more components of the patient's current insulin dosage regimen stored in the memory 10 will constitute the insulin dosage regimen prescribed by the medical professional at the start time of the use of the device, but these data inputs may subsequently change depending on the operation of the device (e.g., during the time interval between the patient's clinic visits). In the above manner, the device is operable to monitor relevant patient data (e.g., at least the patient's blood-glucose-level measurements) with each new information input, thereby facilitating optimization of the patient's insulin dosage regimen between clinic visits.
[0250] It is contemplated that the apparatus broadly defined herein may be embodied in a variety of forms, including purpose-built devices, PDA-like units, commercially available devices such as cell phones, iPhones, etc. Preferably, although not necessarily, such an apparatus will include a data input device, such as a keypad, touch screen interface, etc. (generally shown at dashed box 40), for the initial input of data corresponding to at least the patient's current insulin dosage regimen by a medical professional (and optionally, additional data input, such as (as an example) the patient's current weight, the patient's blood-glucose level measurements defined preferred upper and lower limits, etc.), and subsequent data input corresponding to at least the patient's blood-glucose level measurements measured at multiple times (and optionally, additional data input, such as (as an example) the patient's current weight, the number of insulin units administered by the patient, data corresponding to when the patient ate, the carbohydrate content of the food consumed, the type of meal (such as breakfast, lunch, dinner, snack, etc.). As shown, such a data input device 40 is operably connected (as shown at line 41) to the memory 10.
[0251] The display 30 is operable to provide the patient, medical professional, etc. with a visual display of relevant information, including, by way of non-limiting example, information corresponding to the patient's current insulin dosage regimen, the current insulin dosage (i.e., the number of insulin units that the patient needs to administer based on the most recent blood-glucose-level measurement and the current insulin dosage regimen), etc. To this end, the display 30 is operably connected to the processor 20, as indicated by dashed line 31.
[0252] As mentioned above, the data input device 40 may take the form of a touch screen, in which case the data input device 40 and display 30 may be combined (eg, as exemplified by the commercially available IPHONE (Apple Inc., California)).
[0253] Then, refer to Figures 2 to 5 , depicts a representative image of a display 30 and a touch screen type, combined display 30 / data input device 40 illustrating the patient information that may be provided via the display, as well as the manner in which data may be input.
[0254] More specifically, Figure 2 Display 30 is shown providing current date / time information 32 as well as providing the patient's current blood-glucose-level measurement based on a parallel input of this data. Figure 2Also depicted is a pair of scroll arrows 42 by which the patient can scroll through a predetermined list of selections 34 representing the patient's current blood-glucose-level measurements. As further explained herein in connection with the description of an exemplary algorithm for performing certain embodiments, selecting one of these selections will allow the processor to associate the measurement data with the appropriate measurement time to more accurately control the patient's insulin dosage regimen.
[0255] Figure 3 The display 30 is shown providing current date / time information 32 and - based on the currently defined insulin dosage regimen - providing the patient with the currently recommended dose of a short-acting insulin unit 35 for lunchtime intake.
[0256] Figure 4 The display 30 is shown providing current date / time information 32, and, in accordance with conventional "carbohydrate-counting" therapy, - all based on the currently defined insulin dosing regimen - providing the patient with the currently recommended basal (3 IU) and additional dose (1 IU per 8 grams of ingested carbohydrates) of short-acting insulin units 36 for lunchtime take.
[0257] exist Figure 5 , the display 30 is shown providing the current date / time information 32, and providing the patient with the currently recommended dose of a short-acting insulin unit 37 for lunchtime intake based on the specified amount of carbohydrates to be ingested, based on the currently defined insulin dosage regimen. Figure 5 As further depicted, a pair of scroll arrows 42 are displayed by which the patient can scroll through a list of predetermined meal selections 38, each of which associates a meal in the memory with a number (e.g., grams) of carbohydrates. When the patient selects a meal selection, the processor can determine a recommended dose of short-acting insulin to be taken by the patient (in this example, 22 IU of short-acting insulin for a steak and pasta lunch) based on the number of carbohydrates associated with the meal and the currently defined insulin dosage regimen.
[0258] In one embodiment, Figure 6 As shown in this article about Figure 1 The described device optionally includes a blood glucose meter (indicated by dashed box 50) which is operably connected (as shown at line 51) to the memory 10 to facilitate automatic entry of data corresponding to the patient's blood-glucose level measurements directly into the memory 10.
[0259] Alternatively, it is contemplated that the blood glucose meter 50' may be provided as a separate unit capable of communicating with the apparatus 1' (eg via a cable or wirelessly, as shown at line 51) in order to download the patient's blood-glucose-level measurements to the memory 10', as shown in FIG. Figure 7 as shown in .
[0260] According to another embodiment, Figure 8 As shown in the figure, the device 1 "can be combined with an insulin pump 60" and, optionally, a blood glucose meter 50". According to this embodiment, the processor 20" is operable to determine whether and to what extent to change the patient's current insulin dosage regimen based on at least the patient's blood-glucose-level measurement data (which can be automatically transmitted to the memory 10", wherein the device is provided with a blood glucose meter 50", as shown in the figure, which can be connected to the blood glucose meter so that these data can be automatically downloaded to the memory 10"; or provided with a data input device 40' so that these data can be input by the patient). The processor 20", which is operably connected to the insulin pump 60" (shown at line 61"), is operable to use the insulin dosage regimen information to control the insulin dosage regimen provided via the pump 60". units of insulin supplied to the patient. Thus, the processor 20" and the pump 60" form a semi-automatic closed-loop system that is operable to automatically adjust the infusion rate and profile of the pump based at least on the patient's blood-glucose-level measurements. This will alleviate the burden of having to go to a medical provider to adjust the infusion rate and profile of the insulin pump (as is typically the case). It will be understood that, further with respect to the present embodiment, the insulin pump 60" may be operable to transmit data corresponding to the rate at which insulin is delivered to the patient by the pump according to the patient's current insulin dosage regimen to the memory 10". The processor 20" may access this data to calculate, for example, the amount of insulin units delivered to the patient by the pump within a predetermined time period (such as 24 hours). Such data may therefore be used in certain embodiments to more accurately determine, for example, the patient's insulin sensitivity, plasma glucose correction factor, and carbohydrate ratio.
[0261] Still further with respect to the present embodiment, the device 1" may optionally be provided with a data input device, such as a keypad, a touch screen interface, etc. (generally shown at the dashed box 40"), for inputting data, including, for example, an initial input by a medical professional of data corresponding to at least the patient's current insulin dosage regimen (and optionally, additional data input, such as (as an example) the patient's current weight, defined preferred upper and lower limits for the patient's blood-glucose level measurements, etc.), and subsequent data input corresponding to at least the patient's blood-glucose level measurements measured at multiple times (to the extent that this information is not automatically transferred from the blood glucose meter 50" to the memory 10") and optionally, additional data input, such as (as an example) the patient's current weight, the number of insulin units administered by the patient, data corresponding to when the patient ate a meal, the carbohydrate content of the food consumed, the type of meal (e.g., breakfast, lunch, dinner, snack), etc.
[0262] It is also contemplated that certain embodiments may be implemented with data input from different locations by personnel (e.g., patients and medical professionals), such as Fig. 9 . For example, it is expected that at least the data input about the initial insulin dosage regimen of the patient can be input by a medical professional in the form of a general-purpose computer, mobile phone, IPHONE or other device 100 (depicting a general-purpose computer) at a first location, and subsequent data input (such as patient blood-glucose-level readings) can be input by the patient in the form of a general-purpose computer, mobile phone, IPHONE or other device 200 (depicting a general-purpose computer) at a second location, and these data can be transmitted to a third location in the form of a computer 300 including at least a first memory and a processor. According to this embodiment, computers 100, 200, 300 can be networked in any known manner (including, for example, by the Internet). Such networking is illustrated via lines 101 and 201. Therefore, for example, the system can be executed via a website accessible to medical professionals / patients, and relevant data is input through the website and any updated information related to a predefined treatment plan is transmitted to the patient and medical professionals.
[0263] Alternatively, it is contemplated that certain embodiments may be performed by input of data by persons (e.g., patients and medical professionals) at different locations, and wherein further one of the persons, such as the patient in the illustrated embodiment, possesses a single device 200' including a processor and memory elements, which device 200' is suitable for receiving data input by individuals at different locations. Fig.10. Such a device 200' may take any form, including a general purpose computer (as shown), a PDA, a cell phone, a specially manufactured device, as previously described, and the like. According to this embodiment, it is contemplated that data input regarding at least the patient's initial insulin dose may be entered at another location (e.g., by a medical professional), for example via a general purpose computer, cell phone, or other device 100' (a general purpose computer is depicted) operable to transmit data to the device 200', while subsequent data input (e.g., the patient's blood-glucose-level measurements) may be entered directly into the device 200'. According to this embodiment, the medical professional may remotely enter the patient's initial insulin dose at a first location via the device 100', and that data may then be transmitted to the patient's device 200', where it will be received and stored in its memory. According to a further permutation of this embodiment, the foregoing arrangement may also be reversed such that patient data input (e.g., patient blood-glucose-level measurements) may be input remotely at a first location, such as via a cell phone, computer, etc., and then transmitted to a remotely disposed device including a processor and memory element, which is operable to determine whether and to what extent to change the patient's current insulin dosage regimen. According to this further permutation, modifications to the patient's insulin dosage made by operation of certain embodiments may be transmitted back to the patient via the same or an alternative device.
[0264] See again Fig. 9 It is further contemplated that a blood glucose meter 50"' (including, for example, reference Figure 6 A device such as that described above) can be interfaced 51"' (wirelessly, via a hardwired connection, such as a USB cable, FIREWIRE cable, etc.) with a general purpose computer 200 at the patient's location to download blood-glucose-level measurements for transmission to a computer 300 at a third location. Also refer to Fig.10 It is further contemplated that the blood glucose meter 50'" may be adapted to interface 51'" with a single device 200' (wirelessly, via a hardwired connection such as a USB cable, FIREWIRE cable, etc.) to download blood-glucose-level measurement data directly into the device.
[0265] Now turn to Fig.11 , a diagram outlining the manner in which certain embodiments may be implemented to optimize the insulin dosage regimen of a diabetic patient is shown.
[0266] In certain embodiments, the patient's insulin dosage regimen (composed of, for example, a carbohydrate ratio ("CHR"), a long-acting insulin dose, and a plasma glucose correction factor, etc.) is initially specified by, for example, a medical professional. Alternatively, the initial insulin dosage regimen may be specified using a public protocol for initialization of insulin therapy, such as (by way of example), the protocol published by the American Diabetes Association on October 22, 2008. Although specified, such insulin dosage regimen data is entered into the memory of the device (including according to several embodiments described herein) by, for example, a medical professional at the first instance and before the patient has made any use of the device.
[0267] Thereafter, data corresponding to at least each successive measurement of the patient's blood-glucose-level measurement will be entered by the patient or will be automatically entered (e.g., by a blood glucose meter) into a memory. After such data is entered, the processor determines (e.g., by an algorithm described herein) whether and to what extent the patient's current insulin dosage regimen should be changed. Information corresponding to this current insulin dosage regimen is then provided to the patient so that he / she can adjust the amount of insulin he / she administers.
[0268] According to certain exemplary embodiments, the determination of whether and to what extent to change the patient's current insulin dosage regimen is based on evaluations performed at predetermined time intervals (e.g., every 7 days), and also based on asynchronously proceeding with such time intervals. The asynchronous determination will perform a safety evaluation of the patient's blood-glucose-level data each time a new blood-glucose-level measurement is received to determine whether any emergency action (including any emergency change to the patient's current insulin dosage) is necessary.
[0269] More specifically, each time a new patient blood-glucose-level measurement is received 300 into memory, it is accessed by the processor and categorized and tagged based on the time of day the measurement was received and whether it is associated with an event (e.g., before breakfast, before bedtime, at night, etc. 310). Once so categorized and tagged, new and / or previously recorded blood-glucose-level measurements are subject to evaluation for the need to update based on the passage of a predetermined period of time as measured by a counter 320, and for the sake of safety, for asynchronous updating 330. For example, a very low blood glucose measurement (e.g., below 50 mg / dL) indicating a severe hypoglycemic event, or an accumulation of several low measurements over the past few days, may result in an update to the patient's insulin dosage regimen, according to step 330, whereas an update to such regimen may otherwise be warranted if a predetermined period of time (e.g., 7 days) has passed since the patient's insulin dosage regimen was last updated, according to step 320. In either case, the patient will be provided with information 340 corresponding to the current insulin dosage regimen (whether or not it has been modified) for use in administering his / her insulin.
[0270] See next Fig.12 , shows the flow chart of still setting forth exemplary algorithm more specifically, by which some embodiments of the algorithm can be executed to optimize the insulin dosage scheme of diabetic patients. According to this exemplary algorithm, the insulin dosage modification encompasses the independent unit of long-acting and short-acting insulin. However, it is understood that some embodiments are equally applicable to the insulin dosage scheme of optimizing patients, wherein the dosage is another traditional form (such as premixed insulin). It will also be understood according to this specification that, except specifically described below herein, some embodiments can also be executed in other ways.
[0271] According to a first step 400, data corresponding to a new blood-glucose-level measurement of a patient are input into at least a first memory ( Fig.12 According to the exemplary algorithm, this data is accessed and evaluated (by the processor) at step 410 and sorted according to the time it was entered.
[0272] More specifically, according to this step 410, the blood-glucose-level measurement data input is "tagged" with an identifier reflecting when the reading was entered; specifically, whether it is a morning (i.e., "fasting") measurement (referred to herein as "MPG"), a pre-lunch measurement (referred to herein as "BPG"), a pre-dinner measurement (referred to herein as "LPG"), a bedtime measurement (referred to herein as "BTPG"), or a nighttime measurement (referred to herein as "NPG").
[0273] The "marking" process can be facilitated using a processor internal clock (such as (for example) a general purpose computer clock) that provides an input time that can be associated with the blood-glucose-level measurement data that is synchronized with its input. Alternatively, time data (i.e., "10:00 am," "6:00 pm," etc.) or event identification information (i.e., "lunch time," "dinner time," "before bedtime," etc.) can be entered by the patient to reflect when the blood-glucose-level measurement data was taken, and such information is used to mark the blood-glucose-level measurement data. As a further option, and in accordance with an embodiment in which the blood-glucose-level measurement data is provided directly to a memory by a glucose monitor, time data can be automatically associated with the blood-glucose-level measurement data by such a glucose monitor (e.g., by using a clock internal to the glucose monitor). It is also contemplated that, optionally, the user / patient can be asked (e.g., on a display) whether to enter to confirm or modify any time-tag automatically assigned to the blood-glucose-level measurement data-input. Thus, for example, a patient may be asked (via a data input device, such as, for example, one or more buttons or keys, a touch screen display, etc.) to confirm, based on a timestamp associated with the entry of the most recently entered blood-glucose-level measurement data, that the data reflects a before-lunch (BPG) measurement. If the patient confirms, then the BPG code will remain associated with the measurement. Otherwise, the patient may be further interrogated to determine the appropriate time code associated with the measurement.
[0274] It will be appreciated that any internal clock used to stamp the blood-glucose-level measurement data may, if desired, be user adjustable so as to define the correct time for the time zone in which the patient is located.
[0275] Further, according to an exemplary embodiment, the various categories (e.g., DPG, MPG, LPG, etc.) into which the blood-glucose-level measurement data is more specifically classified through the above-mentioned "labeling" process are as follows:
[0276] NPG--Data is assigned this code when the timestamp is between 2 AM and 4 AM.
[0277] MPG--Data is assigned this code when the timestamp is between 4:00 AM and 10:00 AM.
[0278] BPG--Data is assigned this code when the timestamp is between 10 am and 3 pm.
[0279] LPG--Data is assigned this code when the timestamp is between 3pm and 9pm.
[0280] BTPG--This code is used for data allocation when the timestamp is between 9 PM and 2 AM. If the BTPG data reflects a time that is more than three hours after the patient's estimated dinner time (according to the predefined time window), then this data is further classified as dinner compensatory blood - glucose - level (referred to herein as "DPG").
[0281] Based on the use of the timestamp to "mark" the blood - glucose - level data input separately, it will be understood that there is such a potential assumption that this data was in fact obtained by the patient within the timestamp window specified above.
[0282] According to an exemplary embodiment, if the timestamp of the blood - glucose - level measurement data - input is less than 3 hours from the measurement before the patient's last meal, it is considered to be biased and omitted, unless it represents a hypoglycemic event.
[0283] In the next step 420, the newly - input blood - glucose - level measurement value (by the processor) is accessed and evaluated to determine whether the input reflects a current severe hypoglycemic event. This evaluation can be characterized by the exemplary formula PG(t)<w, where PG(t) represents the patient's blood - glucose - level data in mg / dL, and w represents a predefined threshold that defines a severe hypoglycemic event (e.g., by way of non - limiting example, 50 mg / dL).
[0284] If step 420 indicates a severe hypoglycemic event, then according to step 430, the patient's current insulin dose regimen data (in memory 10 [not shown in Fig.12 ) is updated as warranted and independently of the periodic update evaluation described further below. More specifically, in this step 430, the algorithm will determine whether to update the patient's insulin dose regimen asynchronously (i.e., independently of the periodic update evaluation) based on whether the patient's input blood - glucose - level data reflects the accumulation of several low glucose values within a short period of time. According to an exemplary embodiment, the dose associated with the newly - input blood - glucose - level measurement is immediately reduced. More specifically, for a severe hypoglycemic event at MPG, the long - acting insulin dose is decreased by 20%; and for a severe hypoglycemic event at BPG, the breakfast short - acting insulin dose is decreased by 20%.
[0285] In this step 430, the algorithm also updates the hypoglycemic event counter to reflect the newly - input (in step 400) blood - glucose - level measurement. It is noted that the modification of the patient's insulin dose regimen according to this step 430 does not reset the timer for the next periodic update evaluation. Thus, according to this step 430, the change in the patient's insulin dose regimen does not prevent the algorithm from performing the next periodic update evaluation.
[0286] Any such blood-glucose-level measurements are also entered into a hypoglycemic event database in memory. In an exemplary embodiment, the rolling database is not reset. Instead, the hypoglycemic events recorded in the database expire after a predetermined period of time has passed; essentially, once these data become irrelevant to the patient's insulin dosage regimen. Thus, by way of example only, this database may contain a record of 7 days of hypoglycemic events.
[0287] Further, according to step 430, it is possible (for example, via the display 30 [not shown) Fig.12 ]) generates one or more warnings for display to the patient. It is expected that such one or more warnings will alert the patient to the fact that his / her blood-glucose-level is dangerously low so that appropriate corrective measures (such as taking a glucose tablet) can be taken quickly. Additionally, and without limitation, such one or more warnings may also correspond to any one or more of the following determinations:
[0288] The patient's blood-glucose level measurement data reflects that there have been more than two hypoglycemic events during a predetermined time period (e.g., by way of example only, in the past 7 days); more than two drops in the patient's blood-glucose level measurements between the nighttime measurements and the morning measurements were greater than a predetermined amount in mg / dL (e.g., 70 mg / dL); and / or more than two drops in the patient's blood-glucose level measurements between the nighttime measurements and the morning measurements were greater than a predetermined percentage (e.g., by way of example, 30%).
[0289] If a severe hypoglycemic event is not indicated at step 420, at step 440, the data input recorded (in memory 10) corresponding to the number of hypoglycemic events of the patient over a predetermined period of days is accessed and evaluated by the processor (20, not shown) to determine whether there have been an excessive number of conventional hypoglycemic events (e.g., blood-glucose-level measurements between 50 mg / dL and 75 mg / dL) over the predetermined period of time. This evaluation is directed to determining whether the patient has experienced an excessive number of such conventional hypoglycemic events over an absolute period of time independent of the periodic updating operation described elsewhere herein. This evaluation performed at step 440 can be described by the following exemplary formula:
[0290] Is it (#{HG events}>Q) or (#{hypoglycemic events in the past W days}=Q)?
[0291] Wherein, HG represents the number of recorded hypoglycemic events, W is a predetermined time period (e.g., 3 days), and Q is a predetermined number of hypoglycemic events that define an excessive number (e.g., 3). By way of example, Q may be equal to 3 and W may also be equal to 3, in which case, if it is determined in step 440 that there are 4 recorded hypoglycemic events or there are 3 recorded hypoglycemic events in the past 3 days, the algorithm proceeds to step 430.
[0292] It is noteworthy that if step 440 leads to step 430, the binary ("1" or "0") hypoglycemic event correction "flag" is set to "1", which means that no increase in the insulin dosage regimen of the patient is allowed and the algorithm jumps to step 490 (periodic dose update evaluation routine). Potentially, the periodic update evaluation may agree that any or all parts of the insulin dosage regimen need to be increased due to the nature of the blood-glucose level currently stored in the memory 10 and the execution of the different formulas described below. However, by setting the hypoglycemic event correction flag to "1", the algorithm will ignore any such required increase and will leave the recommended dosage portion unchanged. Therefore, this will result in a potential reduction in any or all components of the insulin dosage regimen to thereby address the occurrence of an excessive number of hypoglycemic events. Further, according to this step, the timer counting to the next periodic update evaluation is reset.
[0293] In the next step 450, the blood-glucose-level measurements recorded and categorized / labeled for the number of hypoglycemic events of the patient over a predetermined period of several days (e.g., 7 days) are accessed and evaluated by the processor to determine whether there have been an excessive number of such hypoglycemic events at any one or more of breakfast, lunch, dinner, and / or in the morning during the predetermined period. Such evaluation can be characterized by the exemplary formula: #{HG(m)(b)(l)(d) in XX[d]}=Y?; wherein #HG(m)(b)(l)(d) represents the number of hypoglycemic events at any of the morning, bedtime, lunch, or dinner measurement times assigned (by the previous step) over a period of XX (in this example, 7) days ("[d]"), and Y represents the number of hypoglycemic events (in this example, 2 hypoglycemic events) predetermined to constitute a threshold sufficient to obtain an adjustment to the insulin dosage regimen of the patient. It will be appreciated that the use of this step in the algorithm allows for greater specificity in identifying possible deficiencies in the patient's current insulin dosage regimen. In addition, further specification of when hypoglycemic events occur may facilitate modification of insulin dosing regimens to be time-specific (eg, after lunch, before bed, etc.).
[0294] If step 450 indicates that there is not an excessive number of such hypoglycemic events, then at step 460 the algorithm asks whether it is time to update the patient's insulin dosage regimen, even though a hypoglycemic event did not occur, and instead based on the passage of a predetermined time interval (e.g., 7 days) since the last assessment of the need to update the patient's insulin dosage regimen, if such an update is not indicated - i.e., because an insufficient time interval has passed - then no action is taken with respect to the patient's insulin dosage and the algorithm ends (indicated by the arrow marked "No") until the next blood-glucose-level measurement data is input.
[0295] However, if the fact that 7 days (or other predetermined interval) have passed since the last assessment of the need to update the patient's insulin dosage indicates an update, then before implementing such an update, the algorithm first determines in step 470 whether the patient's general condition falls within a predetermined "normal" range. This determination operation can be characterized by the exemplary formula: xxx≤E{PG}≤yyy; where xxx represents the lower limit of the patient's expected blood-glucose-level range, yyy represents the upper limit of the patient's expected blood-glucose-level range, and E{PG} represents the average of the patient's recorded blood-glucose-level measurements. According to an exemplary embodiment, the lower limit xxx can be predefined as 80 mg / dL, and the upper limit yyy can be predefined as 135 mg / dL.
[0296] It will be appreciated that the aforementioned values may be defined, for example, based on the particular country in which the patient resides, as not so regulated. In addition, it is contemplated that the upper bound (yyy) and lower bound (xxx) may be defined by the patient's medical professional, for example, via input of a data input device as described elsewhere herein.
[0297] In the event that the patient's general condition is outside of the predetermined "normal" range, the algorithm proceeds to step 490 where the data is evaluated to determine whether a correction to the patient's long-acting insulin dosage regimen is necessary.
[0298] However, in the case where the general condition of the patient is within a predetermined "normal" range, the algorithm then (step 480) asks whether the recorded blood - glucose - level measurement data of the patient represents a normal (e.g., Gaussian) or abnormal distribution. This can be characterized by an exemplary formula: -X < E{PG^3} < X; where E{PG^3} represents the third moment of the recorded (in memory) blood - glucose - level measurement data - i.e., the cube root of the average of the cubic deviations in these data that is approximately equal to the average of the recorded blood - glucose levels, and X represents a predetermined limit value (such as 5). It is expected that the predetermined limit value X should be reasonably close to 0, thus reflecting that the data (E{PG^3}) is well - balanced around the average value.
[0299] Thus, for example, when X is 5, the data is considered normal when the cube root of the average of the cubic deviations of the data that is approximately equal to the average of the recorded blood - glucose levels is greater than - 5 but less than 5. Otherwise, the data is considered abnormal.
[0300] If in step 480 the data is determined to be normal (as indicated by the arrow marked "yes"), then no action is taken to update the patient's insulin - dosage regimen.
[0301] However, if in step 470, the overall average of the patient's recorded blood - glucose - level measurement data is determined to fall outside the predetermined "normal" range, then in step 490, the algorithm evaluates whether it is necessary to correct the patient's long - acting insulin - dosage regimen. This is done by evaluating whether the patient's recorded MPG and BTPG data fall within an acceptable range; or, alternatively, whether there is an indication that the patient's long - acting insulin dosage should be corrected due to low MPG blood - glucose - level measurements. The determination of whether the patient's MPG and BTPG data fall within the predetermined range can be characterized by an exemplary formula: xxy ≤ E{MPG}, E{BTPG} ≤ yyx; where xxy is the lower bound of the blood - glucose - level range desired for the patient, yyx represents the upper bound of the blood - glucose - level range desired for the patient, E{MPG} represents the average of the patient's recorded MPG blood - glucose - level measurements, and E{BTPG} represents the average of the patient's recorded BTPG measurements. According to an exemplary embodiment, xxy can be predefined as 80 mg / dL, and yyx can be predefined as 200 mg / dL. However, it will be understood that these values can be predefined in other ways, including, if needed, by the patient's healthcare provider (e.g., input into memory via a data - entry device).
[0302] If the determination in step 490 is affirmative, then the update of the patient's long-acting insulin dose (step 510) is bypassed and the algorithm proceeds to step 500, whereby the patient's short-acting insulin dose (in the form of a carbohydrate ratio ("CHR")), correction factor Δ, and plasma glucose correction factor are each updated and the hypoglycemia correction "flag" is reset to 0 (thereby allowing subsequent modification of the insulin dose regimen at the next evaluation thereof).
[0303] If, on the other hand, the determination in step 490 is negative, then the patient's long-acting insulin dosage is updated in step 510, and the update indicated in step 500 is performed. In either case, after such an update the process ends until new patient blood-glucose-level measurement data is input.
[0304] The updating of the long-acting insulin dosage regimen data can be represented by the following exemplary formula:
[0305]
[0306] Wherein α(1) represents the percentage by which the patient's current long-acting insulin dosage regimen will be changed, α(2) represents the corresponding binary value (due to the need to quantify the dosage), LD(k) represents the patient's current long-acting insulin dosage, LD(k+1) represents the new long-acting insulin dosage, b1, b2 and b3 represent predetermined blood-glucose-level threshold parameters in mg / dL, and E{MPG} is the average of the patient's recorded MPG blood-glucose-level measurements.
[0307] Since the patient's insulin dosage regimen is expressed in integers (i.e., units of insulin), it is necessary to decide whether a percentage change (increase or decrease) in the current long-acting insulin dosage regimen that is not equal to an integer value should be the nearest higher or lower integer. Thus, for example, if there is a 20% increase in the patient's long-acting insulin dosage regimen from a current regimen of 18 units, it is necessary to decide whether the new dosage should be 21 units or 22 units. In the exemplary algorithm, this decision is made based on the patient's insulin sensitivity.
[0308] Insulin sensitivity is generally defined as the average total number of insulin units administered to a patient per day divided by the patient's weight in kilograms. More specifically, according to the exemplary algorithm, insulin sensitivity (IS(k)) can be defined as a function of twice the patient's total daily dose of long-acting insulin divided by the patient's weight in kilograms (which can be derived from the recorded data corresponding to the patient's current insulin dosage regimen). This is expressed in the following exemplary formula:
[0309]
[0310] where KK is the patient's weight in kilograms.
[0311] The patient's insulin sensitivity factor can of course be approximated by other conventional methods, including but not relying on the input of data corresponding to the patient's weight.
[0312] More specifically, the exemplary algorithm employs an insulin sensitivity correction factor (α (2x1) (IS)))), a 2-entry vector to determine the percentage by which the dose will be corrected and the update of the CHR, PGR and LD for the patient, appropriately rounded to the nearest integer. When the patient's weight is known, this determination can be characterized by the following exemplary formula:
[0313]
[0314] Wherein, α(1) is the percentage value of the adjustment from the current to the new insulin dosage value, and α(2) is a binary value (i.e., 0 or 1). The value of α(2) is defined by the value of IS(k) relative to a predefined percentage change value (e.g., y1, y2, y3, y4) of α(1). Thus, in an exemplary embodiment of the algorithm: where, for example, IS(k)<0.3, the value of α(1) is 5 and the value of α(2) is 0; where, 0.3≤IS(k)<0.5, the value of α(1) is 10 and the value of α(2) is 0; where, 0.5≤IS(k)<0.7, the value of α(1) is 20 and the value of α(2) is 0; and where 0.7≤IS(k), the value of α(1) is 20 and the value of α(2) is 1.
[0315] When the patient's weight is unknown, the algorithm will determine a using the following substitution: If the patient's long-acting insulin dose is greater than X units (where, for example, X may be equal to 50 insulin units), then α(2) is set to "1", and the percentage by which we adjust the dose will be determined based on the average of the blood-glucose-level measurements currently in memory (i.e., E{PG}):
[0316]
[0317] Therein, w1 , w2 and w3 each represent a predefined blood-glucose-level expressed in mg / dL (thus, for example, w1 may be equal to 135 mg / dL, w2 may be equal to 200 mg / dL and w3 may be equal to 280 mg / dL).
[0318] Returning to the exemplary formula for updating the patient's long-acting insulin dosage, in the exemplary algorithm, the decision on whether and to what extent to reduce or increase the patient's long-acting insulin dosage regimen is based on predetermined threshold parameters b1, b2 and b3; where, by way of example only, b1 = 80 mg / dL, b2 = 120 mg / dL and b3 = 200 mg / dL. More specifically, in the event that the average value of the patient's MPG blood-glucose-level data is less than 80 mg / dL, the new long-acting insulin dosage (LD(k+1)) is the current long-acting insulin dosage (LD(k)) minus Δ 下 (which, as indicated above, is a function of the insulin sensitivity correction factors α(1) and α(2), and the patient's long-acting insulin dose (LD(k)), and may be equal to half of Δ.sub.up). Otherwise, if the mean of the patient's MPG blood-glucose-level data is greater than 200 mg / dL, the new long-acting insulin dose (LD(k+1)) is the current long-acting insulin dose (LD(k)) plus Δ 上 Finally, if the mean of the patient's MPG blood-glucose-level data is greater than 150, but less than 200, the new long-acting insulin dose (LD(k+1)) is the current long-acting insulin dose (LD(k)) plus Δ 下 The value of .
[0319] The correction amount Δ is calculated as a percentage of the current long-acting insulin dose rounded according to α(2). In a specific embodiment, if α(1) = 20, α(2) = 0, and the current long-acting insulin dose LD(k) = 58, then Δ.sub.up is equal to 20% of 58, which is 11.6, rounded to Δ 上 = 11. Therefore, the long-acting insulin dose will be updated to LD(k+1)=58+11=69.
[0320] With reference to the foregoing, it will be appreciated that in certain embodiments, a "ping-pong" effect is not permitted; in other words, the adjustment of the patient's long-acting insulin dose may not result in any two consecutive such adjusted doses being both below and above the dose immediately succeeding them. Thus, a result is not permitted in which the latest LD update (LD(2)) is greater than the initial LD (LD(0)) set by the medical professional, and the aforementioned LD update (LD(1)) is less than LD(0). Thus, the result LD(2)>LD(0)>LD(1) is not permitted in certain embodiments.
[0321] Returning to step 450, if the patient's data indicates an excessive number of hypoglycemic events at breakfast, lunch, dinner, or at any time-stamped blood-glucose-level measurement data in the morning over a predetermined time period (e.g., 7 days), then in step 520, the algorithm identifies when these events occurred based on the recorded time-stamped hypoglycemic event data in order to affect any subsequent changes to the patient's insulin dosage regimen, and also sets a binary hypoglycemic correction "flag" (e.g., "1" or "0," where 1 indicates the occurrence of too many hypoglycemic events, and 0 indicates the absence of too many hypoglycemic events) to 1. The presence of this "flag" in the algorithm at this juncture prevents subsequent increases in the patient's insulin dosage regimen in the presence of excessive hypoglycemic events.
[0322] Further, according to this step 520, where the blood-glucose-level measurement data reflects morning or nighttime hypoglycemic events, the algorithm identifies appropriate modifications required for any subsequent changes to the patient's insulin dosage regimen. This can be characterized by the following exemplary formula: If #HG events in {MPG+NTPG} = X, then LD is reduced by α(1) / 2; where #HG is the number of hypoglycemic events recorded for the patient at MPG and NTPG-specified blood-glucose-level measurements, X is a predetermined value (e.g., as an example, 2), LD refers to the long-acting insulin dose, and α(1) represents the aforementioned insulin sensitivity correction factor expressed as a percentage. Therefore, α(1) / 2 reflects that the patient's long-acting insulin dose will only be reduced by 1 / 2 of the value of α(1), if not all of it, where the recorded hypoglycemic event occurs in the morning or overnight.
[0323] Further, according to this step 520, where the blood-glucose-level measurement data reflects hypoglycemic events during the day, the algorithm identifies appropriate modifications required for any subsequent changes to the patient's insulin dosage regimen. This can be characterized by the following formula: if #HG events in {BPG or LPG or NTPG} = X, then see update 6; where #HG is the number of patient hypoglycemic events recorded at any BPG, LPG or NTPG time-stamped measurement, X is a predetermined value (such as 2), and "see update Δ" refers to the short-acting insulin dosage correction factor Δ introduced into the algorithm in exemplary form as described herein.
[0324] Following step 520, the algorithm asks 530 whether it is time to update the patient's insulin dosage regimen, even if a hypoglycemic event has occurred and based on the passage of a predetermined time interval (by way of non-limiting example, 7 days) since the last time an assessment was made of the need to update the patient's insulin dosage regimen. Thus, it is possible that the patient's insulin dosage regimen may not be updated if an insufficient period of time has elapsed since the last update to the regimen, even if the HG correction flag has been "tripped" (indicating the occurrence of excessive hypoglycemic events).
[0325] If the elapsed time period is insufficient, the process ends (indicated by the arrow labeled "NO") until new blood-glucose-level measurement data is input. If, on the other hand, the predetermined time period has elapsed, the algorithm proceeds to step 490 to determine whether the long-acting insulin dose has to be updated, as previously described, followed by an update step 500, whereby each of the patient's short-acting insulin dose (in the form of a carbohydrate ratio ("CHR")), correction factor Δ, and plasma glucose correction factor are updated and the hypoglycemia correction flag is reset to zero.
[0326] According to step 500, an update of the patient's plasma glucose correction factor ("PGR") is performed. This can be characterized by the following exemplary formula:
[0327]
[0328] More specifically, the new PGR ("NPGR") is a function of a predetermined value (e.g., 1700) divided by twice the total daily dose of long-acting insulin for the patient in the current insulin dosage regimen. In the aforementioned formula, the value of the divisor is represented by E{DT} because the value representing twice the total daily dose of long-acting insulin for the patient in the current insulin dosage regimen is substituted as an approximation of the average value of the total daily dose of insulin administered to the patient (if these data are entered into memory by an insulin pump (as in the exemplary device described above) or by the patient using a data input device, they can be optionally used). The resulting value is subtracted from the patient's current PGR(k) ("PGR(k)") to define a difference ("Δ"). If Δ divided by the current PGR(k) is less than or equal to the value of α(1) divided by 100, then the integer value of Δ (the integer to which the new PGR (i.e., PGR(k+1)) is updated) is a function of the formula Δ=(1-α(2)) rounded down {Δ}+α(2) rounded up {Δ}, where α(2) is the insulin sensitivity correction factor (1 or 0), "rounded down" is the value of Δ rounded down to the next integer, and "rounded up" is the value of Δ rounded up to the next integer. If, on the other hand, Δ divided by the current PGR(k) is greater than the value of α(1) divided by 100, then the integer value of Δ is a function of the following formula:
[0329]
[0330] Where α(2) is the insulin sensitivity correction factor (1 or 0), α(1) is the percentage value of the insulin sensitivity correction factor, PGR(k) is the current PGR, "floor" is the Δ value rounded down to the next integer, and "ceiling" is the Δ value rounded up to the next integer. Based on either result, the new PGR (PGR(k+1)) is equal to the current PGR (PGR(k)) plus Δ times the sign function of (NPGR minus PGR(k) positive or negative difference).
[0331] Furthermore, it is contemplated that the new PGR will be quantified as predetermined steps of mg / dL. This is represented by the exemplary formula: PGR(k+1)=quantified(PGR(k+1),ZZ)PGR(k+1)=quantified(PGR(k+1),ZZ); wherein, by way of non-limiting example, ZZ may be equal to 5.
[0332] Still according to the updating step 500, the updating of the short-acting insulin dosage regimen of the patient is performed by modifying the carbohydrate ratio (CHR). The CHR represents the average carbohydrate to insulin ratio required for the patient to determine the correct insulin dosage to be injected before each meal. The method can be characterized by the following exemplary formula:
[0333]
[0334] More specifically, the new CHR ("NCHR") is a function of a predetermined value (e.g., 500) divided by two times the total daily dose of long-acting insulin for the patient in the current insulin dosage regimen. In the aforementioned formula, the value of the divisor is represented by E{DT} because the value representing two times the total daily dose of long-acting insulin for the patient in the current insulin dosage regimen is substituted as an approximation of the average value of the total daily dose of insulin administered to the patient (if these data are entered into memory by an insulin pump (as in the exemplary device described above) or by the patient using a data input device, they can be optionally used). The resulting value is subtracted from the patient's current CHR(k) ("CHR(k)") to define a difference ("Δ"). If Δ divided by the current CHR(k) is less than or equal to the value of α(1) divided by 100, then the integer value of Δ (the integer to which the new CHR (i.e., CHR(k+1)) is updated) is a function of the formula Δ=(1-α(2)) rounded down {Δ}+α(2) rounded up {Δ}, where α(2) is the insulin sensitivity correction factor (1 or 0), "rounded down" is the value of Δ rounded down to the next integer, and "rounded up" is the value of Δ rounded up to the next integer. If, on the other hand, Δ divided by the current CHR(k) is greater than the value of α(1) divided by 100, then the integer value of Δ is a function of the following formula:
[0335]
[0336] Where α(2) is the insulin sensitivity correction factor (1 or 0), α(1) is the percentage value of the insulin sensitivity correction factor, CHR(k) is the current CHR, "floor" is the Δ value rounded down to the next integer, and "ceiling" is the Δ value rounded up to the next integer. Based on either result, the new CHR (CHR(k+1)) is equal to the current CHR (CHR(k)) plus Δ times the sign function of (NCHR minus the positive or negative difference of CHR(k)).
[0337] Because the patient may have different dose responses to short-acting insulin due to the different time of injection that day, different doses of insulin may be needed to compensate for the carbohydrates of similar amounts consumed by breakfast, lunch or dinner. For example, for every `10` gram carbohydrate consumed by lunch, people can use `1` insulin unit, and for every `8` gram carbohydrate consumed by dinner, use `1` insulin unit. In the exemplary embodiment of the algorithm, the realization of this flexibility is through parameter delta δ, which is also updated in step 500. It will be appreciated that the carbohydrate and insulin ratio (CHR) calculated as above are all the same for all meals. However, the actual dosage between meals (i.e. breakfast, lunch, dinner) is different and equal to CHR-δ. Therefore, the exemplary algorithm allows to make dosage more effective by slightly changing CHR with δ to compensate for the individual response of patients to insulin at different times of the day.
[0338] Delta δ is a set of integers representing grams of carbohydrate, and is more specifically defined as a set of values [δb, δl, δd], where "b" represents breakfast, "l" represents lunch, and "d" represents dinner. Delta δ can be positive - reflecting a desire to increase insulin dose before a meal - or negative - reflecting a desire to decrease insulin dose for a given meal due to hypoglycemic events during the day.
[0339] Initially, it is expected that each δ in the group [δb, δl, δd] can be defined by the patient's medical professional or constitute a predetermined value (e.g., for each [b, l, d] or [δb, δl, δd], δ = [0, 0, 0], reflecting that the patient's CHR is used without changing breakfast, lunch, or dinner).
[0340] The range of δ ("Rδ") is defined as the maximum of the three differences, denoted as max(|δb-δI|, |δb-δI|, |δd-δI|). In addition, the algorithm defines the minimum entry ("δmin") of the set [δb, δl, δd], denoted as min[δb, δl, δd].
[0341] Any correction to the patient's CHR can only result in a new Rδ ("Rδ(k+1)") that is less than or equal to a maximum value or a predetermined limit value (D) (which may be, for example, 2) within the range of the current set of δ (Rδ(k)).
[0342] In contrast to the above, if the number of hypoglycemic events (HG) in a given meal (b, l or d) within a predetermined time period (e.g., 7 days) is equal to a predetermined value (e.g., 2), and if the corresponding δb, δl or δd is not equal to δmin or ranges from 0 (R δ=0), then the reduction of δ[δb, δl or δd] is equal to the present value of δ minus a predetermined value ("d"), which may be, for example, 1; therefore, δ {i} =δ {i} -d.
[0343] In addition, if the corresponding δb, δ1 or δd is equal to δ.sub.min, and the range is non-0, then the reduction of the δ (such as δb, δ1 or δd) is achieved by reducing each δ in the group (i.e., [δb, δ1 or δd]) by a predetermined value "d" (such as 1); therefore, δ = δ-d (where δ refers to the entire group [δb, δ1 or δd]).
[0344] If, on the other hand, the number of hypoglycemic events stored in memory is negligible, it may be necessary to increase Δ in one or more of the group (i.e., [δb, δ1, or δd]). To determine whether an increase should be made, the algorithm looks for an unbalanced response to insulin between the three meals (b, l, d). If the average blood-glucose-level measurements associated with two of the three meals fall within a predefined acceptable range (e.g., >α1 but <α2; where, for example, α1=80 and α2=120), while the average of the blood-glucose-level measurements associated with the third meal falls above the predefined acceptable range, the patient's response to his / her most recent short-acting insulin dose is considered to be unbalanced.
[0345] If the mean of two meals falls within [α1, α2], and the mean of the third meal is > α2, then the δ value of the updated group [δb, δ1, or δd] is defined by the following exemplary formula:
[0346] δ tmp =δ;
[0347] δ tmp (i) = δtmp(i) + d;
[0348] If(R δ-tmp <=R δ ) or (R δ-tmp <=D), then δ=δ tmp
[0349] According to the above, it is designated as δ tmp A test group [δb, δ1 or δd] is defined, where the value of each of [δb, δ1 and δd is equal to the current value corresponding to each of δb, δ1 and δd. The δ value corresponding to the meal (b, l or d) in the test group (where the blood-glucose-level measurement is determined to exceed the predetermined acceptable range (e.g.>α2)) is then increased by the value "d" (e.g. 1), and the new group is adopted if it meets one of the following descriptions: R δ-tmp<=Rδ (i.e. the range of the test group R δ (“R δ-tmp ”)) is less than or equal to the range of the current group (R δ ); or R δ-tmp <=D (ie, the range R.sub.Δ of the test group) is less than or equal to a predetermined value "D" (eg, 2).
[0350] If the patient's average blood-glucose-level measurement data is outside a predetermined range, such as, by way of example only, between α1 = 80 and α2 = 120, an increase in the meal-specific insulin dose will therefore be obtained above.
[0351] Further, according to step 500, the binary hypoglycemia correction flag is reset to 0, reflecting that the patient's insulin dosage regimen has been updated (and may therefore be updated again at the next evaluation).
[0352] It will be appreciated that the PGR and CHR values determined in step 500 may alternatively be used by the processor to calculate a "scaling" type insulin dosage regimen by conventional formulas. Such calculations may therefore use the average number of carbohydrates predetermined per meal as a basis. Alternatively, data corresponding to this information may be entered into a memory by the patient using a data input device.
[0353] From the exemplary algorithms described above, it will be appreciated that for certain embodiments, if a hypoglycemic event results in some doses being reduced, no other doses may be increased at the next update cycle.
[0354] It will be noted that according to certain exemplary embodiments of the algorithms described herein, any time a periodic evaluation of the patient's insulin dosage regimen is performed, the algorithm treats the insulin dosage regimen as having been updated even if no changes have been made to the immediately previous insulin dosage regimen. In addition, any time the insulin dosage regimen is updated, whether as a result of a periodic update evaluation or an asynchronous update, the timer counting to the next periodic update evaluation is reset to zero.
[0355] As previously mentioned, in the operation of certain embodiments, initially specified by a medical professional, the patient's insulin dosage regimen is composed of, for example, a long-acting insulin dosage component, a carbohydrate ratio component, and a plasma-glucose correction factor component. This insulin dosage regimen data is input to the memory of the device by, for example, a medical professional in the first instance and before the patient has made any use of the device. Optionally, and when necessary, the internal clock of the device is set to the correct time for the time zone where the patient is located, so that when they are subsequently input to the device, the time label of the blood-glucose-level measurement value assigned to the patient is accurate about when the data is actually input (automatically, manually, or a combination of the two). Thereafter, the patient will input or will otherwise automatically input (for example, by a blood glucose meter) data corresponding to each continuous value of the patient's blood-glucose-level measurement value to the memory. After such data is input, the processor, for example, via the algorithm described above, determines whether and to what extent the current insulin dosage regimen of the patient is changed. The information corresponding to this current insulin dosage regimen is then provided to the patient so that he / she can adjust the amount of insulin administered by it.
[0356] Although the present disclosure has been described in conjunction with certain embodiments, it will be understood that the present disclosure is not limited to the disclosed embodiments, but on the contrary, is intended to cover various modifications and equivalent arrangements. In addition, the various embodiments described herein may be implemented in conjunction with other embodiments, for example, aspects of one embodiment may be combined with aspects of another embodiment to achieve other embodiments. In addition, each independent feature or component of any given component may constitute an additional embodiment. DETAILED DESCRIPTION
[0357] 1. A method for treating diabetes by reducing glucose toxicity and / or restoring pancreatic beta cell function in a patient, the method comprising:
[0358] storing one or more components of the patient's insulin dosage regimen;
[0359] drawing blood samples from the patient at various times;
[0360] determining a blood glucose-level measurement of the patient in said blood sample;
[0361] tagging each of said blood glucose-level measurements with an identifier reflecting when said measurement was obtained;
[0362] establishing the patient's current glycemic status relative to an expected glycemic range;
[0363] determining whether and to what extent to adjust at least one of the one or more components of the patient's current insulin dosage regimen based on the patient's blood glucose-level measurement to remain within the desired glycemic range and administer a minimum insulin dosage;
[0364] adjusting the at least one component based on the determination; and
[0365] The steps of the method are performed until the insulin dosage regimen required to remain within the desired glycemic range is reduced to a predetermined level.
[0366] 2. The method according to embodiment 1, wherein the adjustment of the patient's insulin dosage regimen is performed essentially in real time.
[0367] 3. The method according to embodiment 1, wherein the initial insulin dosage regimen is provided by a physician or other medical professional.
[0368] 4. The method according to embodiment 1, wherein the method is performed without any intervention by a physician or other medical professional.
[0369] 5. The method of embodiment 1, wherein the desired blood glucose range changes over time and adjustments to the patient's insulin dosage regimen are to be made to be within the most recent desired blood glucose range.
[0370] 6. The method of embodiment 1, wherein the identifier reflecting when the reading was obtained is selected from the group consisting of breakfast, lunch, dinner, bedtime, nighttime, and others.
[0371] 7. A method according to embodiment 8, wherein the measurement values labeled "other" are classified based on the classification of the previous measurement value and the time elapsed since the previous measurement value.
[0372] 8. The method of embodiment 1, wherein the desired blood glucose range is defined as blood glucose-level measurements between 85 mg / dL and 200 mg / dL.
[0373] 9. The method according to embodiment 1, wherein the steps of the method are repeated for a sufficient time to achieve a sustained blood sugar balance.
[0374] 10. The method according to embodiment 1, wherein the patient's insulin dosage regimen is adjusted to include at least one high insulin dose.
[0375] 11. The method according to embodiment 1, wherein the patient's insulin dosage regimen is adjusted so that no insulin is no longer administered.
[0376] 12. A method for treating diabetes by reducing glucose toxicity and / or restoring pancreatic beta cell function in a patient, the method comprising:
[0377] storing one or more components of the patient's insulin dosage regimen;
[0378] drawing blood samples from the patient at various times;
[0379] determining a blood glucose-level measurement of the patient in said blood sample;
[0380] tagging each of said blood glucose-level measurements with an identifier reflecting when said measurement was obtained;
[0381] establishing the patient's current glycemic status relative to an expected glycemic range;
[0382] determining whether and by what degree to adjust at least one of the one or more components of the patient's current insulin dosage regimen based on the patient's blood glucose-level measurement to remain within the desired glycemic range and administer a minimum insulin dosage;
[0383] adjusting the at least one component based on the determination in a manner to suppress or prevent unstable oscillations; and
[0384] The steps of the method are performed until the insulin dosage regimen required to remain within the desired glycemic range is reduced to a predetermined level.
[0385] 13. The method of embodiment 12, wherein the unstable oscillations are suppressed or prevented by ensuring that the regulation is limited to intermittent values.
[0386] 14. The method of embodiment 12, wherein the unstable oscillations are suppressed or prevented by ensuring that a current increase in the patient's insulin dosage regimen is less than a previous decrease in the patient's insulin dosage regimen.
[0387] 15. The method of embodiment 12, wherein the unstable oscillations are suppressed or prevented by ensuring that a current decrease in the patient's insulin dosage regimen is less than a previous increase in the patient's insulin dosage regimen.
[0388] 16. The method according to embodiment 12, wherein the unstable oscillations are suppressed or prevented by inserting 'off-time intervals' between dosage adjustments in different directions.
[0389] 17. The method according to embodiment 12, wherein said determination whether and to what extent to adjust at least one component of the patient's current insulin dosage regimen is performed by calculating the total daily amount of insulin.
[0390] 18. The method of embodiment 12, wherein said determination of whether and by how much to adjust at least one component of the patient's current insulin dosage regimen is performed by calculating the amount by which any component of the dose is greater than the same component of a previous dose.
[0391] 19. The method of embodiment 12, wherein said determination of whether and by how much to adjust at least one component of the patient's current insulin dosage regimen is performed by majority voting rule.
[0392] 20. A method according to embodiment 12, wherein the determination of whether and by how much to adjust at least one component of the patient's current insulin dosage regimen is subject to a continuous dosage increment rule so that a rest period is established if more than a required number of increments have occurred.
[0393] 21. The method of embodiment 21, wherein the consecutive dose increment rule prevents the occurrence of two consecutive increments and establishes a rest period after each dose increment.
[0394] 22. The method of embodiment 21, wherein the consecutive dose increment rule allows more than two consecutive increments, but no more than eight consecutive increments.
[0395] 23. A method for updating a patient's insulin dosage regimen to reduce glucose toxicity and / or restore pancreatic beta cell function, the method comprising:
[0396] storing one or more components of the patient's insulin dosage regimen;
[0397] drawing blood samples from the patient at various times;
[0398] determining a blood glucose-level measurement of the patient in said blood sample;
[0399] incrementing a timer based on at least one of the passage of a predetermined amount of time and receipt of each blood glucose-level measurement;
[0400] tagging each of said blood glucose-level measurements with an identifier reflecting when said measurement was obtained;
[0401] establishing the patient's current glycemic status relative to an expected glycemic range;
[0402] determining, based on the patient's blood glucose-level measurement, whether and to what extent at least one of the one or more components of the patient's current insulin dosage regimen should be adjusted to remain within the desired glycemic range with a minimum insulin dosage;
[0403] updating the at least one component of the patient's insulin dosage regimen responsive to the determination; and
[0404] The above steps of the method are performed until the insulin dosage regimen required to remain within the desired blood glucose range is reduced to a predetermined level.
[0405] 24. A method according to embodiment 23, wherein it is determined that there have been an excessive number of blood-glucose measurements that are not within the expected glycemic range with the lowest insulin dose within a predetermined time period, and in response to the determination, an update of at least one of the one or more components of the patient's insulin dosage regimen is completed; and the timer is reset.
[0406] 25. A method according to embodiment 24, wherein the timer is configured to indicate that the step of determining whether and to what extent at least one of the one or more components of the patient's current insulin dosage regimen should be adjusted based on the patient's blood glucose level measurement should be performed after 7 days.
[0407] 26. A method according to embodiment 23, wherein the timer indicates when to perform the step of determining whether and to what extent at least one of the one or more components of the patient's current insulin dosage regimen should be adjusted based on the patient's blood glucose level measurement, and the timer is reset.
[0408] 27. The method of embodiment 23, wherein the desired blood glucose range changes over time and updates to the patient's insulin dosage regimen are to be made to be within the most recent desired blood glucose range.
[0409] 28. The method according to embodiment 27, wherein the patient's insulin dosage regimen is updated in a manner that dampens or prevents unstable oscillations.
[0410] 29. The method of embodiment 27, wherein the range of the oscillation is reduced by ensuring that a current increase in the patient's insulin dosage regimen is less than a previous decrease in the patient's insulin dosage regimen.
[0411] 30. The method of embodiment 23, wherein the identifier reflecting when the reading was obtained is selected from the group consisting of breakfast, lunch, dinner, bedtime, nighttime, and others.
[0412] 31. A method according to embodiment 30, wherein the measurement values labeled "other" are classified based on the classification of the previous measurement value and the time elapsed since the previous measurement value.
[0413] 32. The method of embodiment 23, wherein the desired blood glucose range is defined as blood glucose-level measurements between 85 mg / dL and 200 mg / dL.
[0414] 33. The method of embodiment 23, wherein the steps of the method are repeated for a sufficient time to achieve sustained glycemic balance.
[0415] 34. The method of embodiment 23, wherein the patient's insulin dosage regimen is updated to include at least one high insulin dose.
[0416] 35. The method of embodiment 23, wherein the patient's insulin dosage regimen is updated so that no insulin is no longer administered.
[0417] 36. A device for alleviating glucose toxicity and / or restoring pancreatic beta cell function in a patient over time, comprising:
[0418] at least a first computer-readable memory for storing one or more components of a patient's current insulin dosage regimen and blood-glucose-level measurements of the patient taken at a plurality of times over a predetermined period of time;
[0419] at least one data input for obtaining data corresponding to blood glucose-level measurements of the patient determined at the plurality of times;
[0420] a timer for monitoring the predetermined period of time, the timer being incremented based on at least one of the passage of predetermined time increments and receipt of at least one of a plurality of blood glucose-level measurements;
[0421] at least one processor operably connected to the at least first computer readable memory, the processor being programmed to at least:
[0422] labeling the plurality of blood glucose-level measurements with an identifier reflecting when the measurements were obtained;
[0423] calculating any deviation of the obtained blood glucose-level measurement from the expected glycemic range after obtaining one of the plurality of blood glucose-level measurements but before obtaining a subsequent blood glucose-level measurement; adjusting at least one of the one or more components of the patient's insulin dosage regimen in response to a determination that a most recently obtained blood glucose-level measurement is not within the expected glycemic range; wherein the timer is reinitialized after a determination that a most recently obtained blood glucose-level measurement is not within the expected glycemic range within the predetermined time period;
[0424] at the end of the predetermined time period, determining, based on a plurality of data corresponding to the patient's blood glucose-level measurements, a change in at least one of the one or more components of the patient's insulin dosage regimen that is necessary to maintain the patient's blood glucose-level measurements within a predetermined range;
[0425] reinitializing the timer after the adjusting and the determining; and
[0426] The measurements, calculating the deviation, adjusting the at least one component, and determining the change are iteratively performed until the insulin dosage regimen required to remain within the desired glycemic range is reduced to a predetermined level.
[0427] 37. Device according to embodiment 36, wherein the data input device enables a user to modify the identifier associated with each blood-glucose-level measurement data-input.
[0428] 38. The device according to embodiment 36, wherein the at least one processor further determines whether and to what extent to change at least one of the one or more components of the patient's current insulin dosage regimen according to a predetermined schedule.
[0429] 39. An apparatus according to embodiment 36, wherein the at least one processor further determines, at the end of the predetermined time period, whether the patient's blood-glucose level measurement value falls within or outside the predetermined range based on the multiple data corresponding to the patient's blood-glucose level measurement value, and changes at least one of the one or more components in the patient's current insulin dosage regimen only when the patient's blood-glucose level measurement value falls outside the predetermined range.
[0430] 40. The device according to embodiment 36, wherein the at least one processor further determines based on the patient's blood-glucose-level measurements whether the patient's blood-glucose-level measurements indicate a normal distribution.
[0431] 41. An apparatus according to embodiment 40, wherein the determination of whether the patient's blood-glucose level measurements represent a normal distribution comprises determining whether a third moment of the distribution of the patient's blood-glucose level measurements falls within the predetermined range.
[0432] 42. The device of embodiment 36, wherein the one or more components of the patient's current insulin dosage regimen include a long-acting insulin dosage component.
[0433] 43. The device of embodiment 36, wherein the one or more components of the patient's current insulin dosage regimen include a short-acting insulin dosage component defined by a carbohydrate ratio or a fixed meal dose, and a plasma glucose correction factor.
[0434] 44. A system for alleviating glucose toxicity and / or restoring pancreatic beta cell function in a patient, the system comprising:
[0435] at least one memory for storing data corresponding at least to one or more components of a patient's current insulin dosage regimen and at least to blood-glucose-level measurements of the patient measured at a plurality of times during a predetermined period of time;
[0436] and at least one processor operably connected to the at least one memory, the at least one processor being configured to:
[0437] Initializing a timer to monitor the predetermined time period;
[0438] incrementing the timer based on at least one of the passage of a predetermined time increment and receipt of at least one of a plurality of blood glucose-level measurements;
[0439] labeling the plurality of blood glucose-level measurements with an identifier reflecting when the measurements were obtained;
[0440] calculating any deviation of the obtained blood glucose-level measurement from an expected glycemic range after obtaining one of the plurality of blood glucose-level measurements but before obtaining a subsequent blood glucose-level measurement; adjusting at least one of the one or more components of the patient's insulin dosage regimen in response to the determination that the most recently obtained blood glucose-level measurement is not within the expected glycemic range; wherein the timer is reinitialized after the determination of not being within the expected glycemic range; and
[0441] At the end of the predetermined time period, determining whether and to what extent to change at least one of the one or more components of the patient's current insulin dosage regimen in order to maintain the patient's blood glucose-level measurement within a predetermined range based on a plurality of data corresponding to the patient's blood glucose-level measurement; wherein after the determination whether and to what extent to change at least one of the one or more components of the patient's current insulin dosage regimen, the timer is reinitialized; and
[0442] Incrementing the timer, marking the measurements, calculating the deviation, adjusting the at least one component, and determining the change are repeated until the insulin dosage regimen required to remain within the desired glycemic range is reduced to a predetermined level.
[0443] 45. The system of embodiment 44, wherein the at least one memory and the at least one processor are located in a single device.
[0444] 46. The system of embodiment 45, wherein the single device further comprises a blood glucose meter.
[0445] 47. The system according to embodiment 45, further comprising a blood glucose meter separate from the single device, the blood glucose meter being adapted to transmit data corresponding at least to blood-glucose level measurements of the patient determined at multiple times to the at least one memory of the single device.
[0446] 48. A system according to embodiment 45, wherein the single device further comprises data input means for inputting data corresponding at least to blood-glucose-level measurements of the patient determined at multiple times directly into the at least one memory.
[0447] 49. The system according to embodiment 48 further comprises a data input device, which is arranged at a remote location of the single device, for remotely inputting data corresponding to at least one or more components in the patient's current insulin dosage regimen into the at least one memory.
[0448] 50. The system according to embodiment 44 further comprises at least a first data input device, which is arranged at a remote location of the at least one memory and the at least one processor, for remotely inputting data corresponding to at least one or more components in the patient's current insulin dosage regimen into the at least one memory; and at least a second data input device, which is arranged at a remote location of the at least one memory, the at least one processor and the at least first data input device, for remotely inputting data corresponding to at least blood-glucose level measurements of the patient measured at multiple times into the at least one memory.
[0449] 51. A system according to embodiment 44, wherein the data corresponding at least to blood-glucose-level measurements of the patient determined at multiple times are associated with an identifier indicating when the measurements were entered into the memory.
[0450] 52. The system according to embodiment 51, further comprising data input means enabling a user to define the identifier associated with the blood-glucose-level measurement data.
[0451] 53. The system according to embodiment 51, further comprising data input means enabling a user to confirm the correctness of the identifier associated with the blood-glucose-level measurement data.
[0452] 54. The system according to embodiment 51, further comprising data input means enabling a user to modify the identifier associated with each blood-glucose-level measurement data.
[0453] 55. The system of embodiment 44, wherein the processor is programmed to determine whether and to what extent to change at least one of the one or more components of the patient's current insulin dosage regimen on a predetermined schedule.
[0454] 56. A system according to embodiment 44, wherein the processor is programmed to determine whether the patient's blood-glucose level measurement falls within or outside the expected glycemic range based on data input corresponding to at least the patient's blood-glucose level measurement determined at multiple times, and to change at least one of the one or more components in the patient's current insulin dosage regimen only when the patient's blood-glucose level measurement falls outside the expected glycemic range.
[0455] 57. A system according to embodiment 56, wherein the processor is further programmed to determine whether the patient's blood-glucose level measurements measured at multiple times represent a normal or non-normal distribution based on the data input corresponding at least to the patient's blood-glucose level measurements measured at multiple times.
[0456] 58. A system according to embodiment 56, wherein determining whether the patient's blood-glucose level measurements measured at multiple times represent a normal or non-normal distribution includes determining whether the third moment of the distribution of the patient's blood-glucose level measurements measured at multiple times falls within the expected blood glucose range.
[0457] 59. A system according to embodiment 51, wherein the one or more components in the patient's current insulin dosage regimen include a long-acting insulin dosage component, and wherein the processor is programmed to determine whether the measurement value is a morning or a bedtime blood-glucose level measurement based at least on the identifier indicating when the measurement value was entered into the memory, to determine whether the patient's morning and bedtime blood-glucose level measurements fall within a predetermined range, and to determine to what extent to change the patient's long-acting insulin dosage component only if it is determined that the patient's morning and bedtime blood-glucose level measurements fall outside of the expected glycemic range.
[0458] 60. A system according to embodiment 59, wherein in connection with determining by what degree to change at least one of the one or more components of the patient's current insulin dosage regimen, the at least one processor is programmed to take into account an insulin sensitivity correction factor that defines the percentage by which any of the one or more components of the insulin dosage regimen is changed and the direction in which any fractional changes in any of the one or more components are rounded to the nearest integer.
[0459] 61. The system of embodiment 60, wherein the at least one memory further stores data corresponding to the patient's current weight, and wherein the insulin sensitivity correction factor is determined in part based on the patient's current weight.
[0460] 62. A system according to embodiment 60, wherein the determination of the degree to which to change the long-acting insulin dosage component of the patient's current insulin dosage regimen is a function of the current long-acting insulin dosage, the insulin sensitivity correction factor, and the patient's blood-glucose level measurement.
[0461] 63. A system according to embodiment 44, wherein the one or more components in the patient's current insulin dosage regimen include a short-acting insulin dosage component defined by a carbohydrate ratio and a plasma glucose correction factor, and wherein the processor is programmed to determine whether and to what extent to change the patient's carbohydrate ratio and plasma glucose correction factor.
[0462] 64. A system according to embodiment 63, wherein in connection with determining the extent to which to change at least one of the one or more components of the patient's current insulin dosage regimen, the at least one processor is programmed to take into account an insulin sensitivity correction factor that defines the percentage by which any one or more components of the insulin dosage regimen are changed and the direction in which any fractional changes in the one or more components are rounded to the nearest integer.
[0463] 65. A system according to embodiment 64, wherein the determination of the current plasma glucose correction factor as to what extent to change the patient's insulin dosage regimen is a function of a predetermined value divided by the total daily dose of insulin administered to the patient, the patient's current plasma glucose correction factor, and the average of the insulin sensitivity correction factor.
[0464] 66. A system according to embodiment 65, wherein a value representing twice the daily dose of the patient's long-acting insulin in the current insulin dosage regimen is substituted as an approximation of the average total daily dose of insulin administered to the patient.
[0465] 67. The system of embodiment 65, wherein the plasma glucose correction factor component of the patient's insulin dosage regimen is quantified into predetermined steps of mg / dL.
[0466] 68. A system according to embodiment 64, wherein the determination of how much to change the current carbohydrate ratio component of the patient's insulin dosage regimen is a function of a predetermined value divided by the total daily dose of insulin administered to the patient, the patient's current carbohydrate ratio, and the average of the insulin sensitivity correction factor.
[0467] 69. A system according to embodiment 68, wherein a value representing twice the daily dose of the patient's long-acting insulin in the current insulin dosage regimen is substituted as an approximation of the average total daily dose of insulin administered to the patient.
[0468] 70. The system of embodiment 68, wherein the at least one processor is programmed to determine a correction factor that allows for variations in changes to the carbohydrate ratio component of the patient's insulin dosage regimen to compensate for the patient's individual response to insulin at different times of the day.
[0469] 71. A system according to embodiment 44, wherein the one or more components of the patient's current insulin dosage regimen include a long-acting insulin dosage component, and the determination of how much to change the long-acting insulin dosage component is limited to a change within a predetermined range.
[0470] 72. A system according to embodiment 44, wherein the one or more components in the patient's current insulin dosage regimen include a short-acting insulin dosage component defined by a carbohydrate ratio and a plasma glucose correction factor, and the determination of the extent to which any one or more of the components in the short-acting insulin dosage is changed is limited to a change within a predetermined range.
[0471] 73. A system according to embodiment 44, wherein the one or more components of the patient's current insulin dosage regimen include a short-acting insulin dosage component administered according to a proportional reduction regimen, and the processor is programmed to determine whether and to what extent to at least change the proportional reduction regimen so as to keep future blood-glucose level measurements of the patient within a predetermined range.
[0472] 74. A system according to embodiment 73, wherein the determination of how much to change the proportional increase or decrease system is limited to the amount of change within a predetermined range.
Claims
1. Devices for alleviating glucose toxicity and / or restoring pancreatic beta cell function in a patient over time, comprising: at least a first computer-readable memory for storing one or more components of a patient's current insulin dosage regimen and blood-glucose-level measurements of the patient taken at a plurality of times over a predetermined period of time; at least one data input for obtaining data corresponding to blood glucose-level measurements of the patient determined at the plurality of times; a timer for monitoring the predetermined period of time, the timer being incremented based on at least one of the passage of predetermined time increments and receipt of at least one of a plurality of blood glucose-level measurements; at least one processor operably connected to the at least first computer readable memory, the processor being programmed to at least: labeling the plurality of blood glucose-level measurements with an identifier reflecting when the measurements were obtained; after obtaining one of the plurality of blood glucose-level measurements, but before obtaining a subsequent blood glucose-level measurement, calculating any deviation of the obtained blood glucose-level measurement from an expected glycemic range; adjusting at least one of the one or more components of the patient's insulin dosage regimen in response to a determination that a most recently obtained blood glucose-level measurement is not within an expected glycemic range; wherein the timer is reinitialized after a determination that a most recently obtained blood glucose-level measurement is not within the expected glycemic range within the predetermined time period; determining, at the end of the predetermined time period, a change in at least one of the one or more components of the patient's insulin dosage regimen based on a plurality of data corresponding to blood glucose-level measurements of the patient, The change is necessary to maintain the patient's blood glucose-level measurement within a predetermined range; Determining whether to adjust the insulin dosage regimen by increasing, decreasing, or suspending the patient's dosage regimen, thereby adjusting the patient's insulin dosage regimen to suppress or prevent unstable oscillations, wherein the adjustment simultaneously considers the weighting of both the A1C percentage and hypoglycemic events within the predetermined time period to achieve an improved glycemic index and restoration of beta cell function, thereby reducing dependence on exogenous insulin; reinitializing said timer after said adjusting and said determining; as well as The measurements, calculating the deviation, adjusting the at least one component, and determining the change are iteratively performed until the insulin dosage regimen required to remain within the desired glycemic range is reduced to a predetermined level.
2. A device according to claim 1, wherein the data input device enables a user to modify the identifier associated with each blood-glucose-level measurement data-input.
3. The device according to claim 1, wherein the at least one processor further determines whether and to what extent to change at least one of the one or more components of the patient's current insulin dosage regimen on a predetermined schedule.
4. An apparatus according to claim 1, wherein the at least one processor further determines, at the end of the predetermined time period, whether the patient's blood-glucose level measurement value falls within or outside the predetermined range based on the multiple data corresponding to the patient's blood-glucose level measurement value, and changes at least one of the one or more components in the patient's current insulin dosage regimen only when the patient's blood-glucose level measurement value falls outside the predetermined range.
5. The device according to claim 1, wherein the at least one processor further determines based on the patient's blood-glucose-level measurements whether the patient's blood-glucose-level measurements represent a normal distribution.
6. An apparatus according to claim 5, wherein the determination of whether the patient's blood-glucose level measurements represent a normal distribution comprises determining whether a third moment of the distribution of the patient's blood-glucose level measurements falls within the predetermined range.
7. The device according to claim 1, wherein the one or more components of the patient's current insulin dosage regimen include a long-acting insulin dosage component.
8. The apparatus according to claim 1, wherein the one or more components of the patient's current insulin dosage regimen include a short-acting insulin dosage component defined by a carbohydrate ratio or a fixed meal dose, and a plasma glucose correction factor.
9. A system for alleviating glucose toxicity and / or restoring pancreatic beta cell function in a patient, the system comprising: at least one memory for storing data corresponding at least to one or more components of a patient's current insulin dosage regimen and at least to blood-glucose-level measurements of the patient measured at a plurality of times during a predetermined period of time; and at least one processor operably connected to the at least one memory, the at least one processor being configured to: Initializing a timer to monitor the predetermined time period; incrementing the timer based on at least one of the passage of a predetermined time increment and receipt of at least one of a plurality of blood glucose-level measurements; labeling the plurality of blood glucose-level measurements with an identifier reflecting when the measurements were obtained; after obtaining one of the plurality of blood glucose-level measurements, but before obtaining a subsequent blood glucose-level measurement, calculating any deviation of the obtained blood glucose-level measurement from an expected glycemic range; adjusting at least one of the one or more components of the patient's insulin dosage regimen in response to a determination that: a most recently obtained blood glucose-level measurement is not within an expected glycemic range; in reinitializing the timer after a determination of not being within an expected blood glucose range; as well as At the end of the predetermined time period, determining whether and to what extent to change at least one of the one or more components of the patient's current insulin dosage regimen in order to maintain the patient's blood glucose-level measurement within a predetermined range based on a plurality of data corresponding to the patient's blood glucose-level measurement; determining whether to adjust the patient's insulin dosage regimen by increasing, decreasing, or pausing the patient's dosage regimen, thereby adjusting the patient's insulin dosage regimen to suppress or prevent unstable oscillations, wherein the adjustment simultaneously considers the weighting of both the A1C percentage and hypoglycemic events within the predetermined time period to achieve an improved glycemic index and restoration of beta cell function, thereby reducing dependence on exogenous insulin; wherein after determining whether and to what extent to change at least one of the one or more components of the patient's current insulin dosage regimen, reinitializing the timer; as well as repeatedly incrementing the timer, marking the measured value, calculating the deviation, adjusting the at least one component, and determining a change in at least one of the one or more components in the patient's insulin dosage regimen, Until the insulin dosage regimen required to maintain within the desired blood glucose range is reduced to a predetermined level.
10. The system of claim 9, wherein the at least one memory and the at least one processor are located in a single device.
Citation Information
Patent Citations
System for optimizing a patient's insulin dosage regimen
US10272198B2
Apparatus for optimizing a patient's insulin dosage regimen
US10335546B2
Multiple device types including an inverted-t channel transistor and method therefor
US20090039418A1
Nitride semiconductor device and method for producing nitride semiconductor device
US20090039421A1
Methods and Devices for Reconstructing Visual Stimuli Observed Through Browser-Based Interfaces Over Time
US20090063989A1
